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ABSTRACT 
Transposable elements (TEs) are mobile genetic elements that constitute a large 
fraction of eukaryotic genomes. TEs co-evolved with their host genomes, providing 
powerful tools of genome plasticity and regulation.  
Long Interspersed Nuclear Elements 1 (L1) are the most numerous TEs in mouse 
and human genomes. They mobilize via a “copy and paste” mechanism that requires an 
RNA intermediate. Although most L1s have lost their activity during evolution, the 
remaining subset continues to move both in the germline and in adult somatic tissues. 
Mounting evidence suggests that L1s are active in somatic cells of the mammalian 
brain and that dysregulated activation of L1s is associated with neuropathology, such as 
schizophrenia, Rett syndrome and Ataxia telengectasia.  
Huntington’s disease (HD) is an autosomal dominant disorder that manifests in 
mid-life and is characterized by neuronal loss, prominently in striatum and deep layers 
of the cerebral cortex. Typical HD-associated phenotypes include somatic genomic 
instability, epigenetic and transcriptional dysregulations, impaired neurogenesis and 
altered DNA damage response. At the same time, in HD, the origin and the role of many 
genetic and epigenetic modifiers acting on disease onset and progression remain largely 
unknown.  
In this scenario, I investigated whether L1 retrotransposition might be altered in 
HD and if it could have a role in HD pathogenesis.  
To address this question, using a novel Taqman qPCR technique, I characterized 
endogenous L1 retrotransposition events in the brains of a precise genetic mouse model 
of HD, considering both pre-symptomatic and symptomatic developmental stages. From 
this study, I showed that similar levels of L1 genomic copies are present between HD 
and control brains. Moreover, differences in full length L1 transcript levels have been 
reported in HD brains. Interestingly, in HD striatum, at 12 months of age, expression of 
full length L1s was consistently impaired, whereas in the cortex, L1 mRNA levels were 
increased in HD mice at 3 months and 24 months of age.  
The dysregulation of L1 expression in the striatum of 12 months old mice did not 
appear to be linked to differential deposition of H3K4me3, H3K9me3, H3K27me3 and 
MeCP2 on L1 promoter in HD conditions. Nonetheless, L1 transcriptional alterations 
might involve a piRNA-mediated regulation. Indeed, in both cortex and striatum of 
adult HD and control mice I detected appreciable levels of MILI protein, the crucial 
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factor of piRNA biogenesis, suggesting its role not only in the germline but also in adult 
mammalian brains, as recently proposed by other two independent works.  
Additionally, I showed that in a subset of neurons of the adult mouse pre-frontal 
cortex, endogenous L1 transcription is accompanied by expression of L1-encoded 
ORF2 protein. 
Finally, by characterizing the transcription of active murine full length L1 
elements in a broad range of developmental stages (from E10 up to 24 months), I 
described the expression profiles of endogenous L1 elements during the entire mouse 
development. From this study, I showed that a wave of L1 transcription takes place 
between E12 and P0 in both striatum and cerebral cortex and it is concomitant with 
telencephalic neurogenesis. In post-natal stages, L1 transcription is maintained at basal 
levels.  
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ABBREVIATIONS 
ASP  Antisense Promoter 
ChIP  Chromatin Immunoprecipitation 
CNV  Copy Number Variation 
DSB  Double Strand Break 
dsDNA  Double Strand DNA 
E  Embryonal day 
EN  Endonuclease 
gDNA  genomic DNA 
H3K4me3 Tri-methylated Lys4 on Histone 3 
H3K9me3 Tri-methylated Lys9 on Histone 3 
H3K27me3 Tri-methylated Lys27 on Histone 3 
HD  Huntington's disease 
Htt  Huntingtin 
IHC  Immunohistochemistry 
KI  Knock-in 
L1  LINE1, Long Interspersed Nuclear Element 1 
LTR  Long Terminal Repeat 
MeCP2  Methyl-CpG binding protein 2 
MILI  murine Piwi-like protein 2 
MIWI2  murine Piwi-like protein 4 
mHtt  Mutant Huntingtin 
mo  months 
ORF  Open Reading Frame 
ORF2p   ORF2 protein 
PCR  Polymerase Chain Reaction 
piRNA  Piwi-interacting RNA 
poly-Q  poly-Glutamine 
PRC2  Polycomb Repressive Complex 2 
qPCR  quantitative PCR 
RISC  RNA-Induced Silencing Complex 
RNP   Ribonucleoprotein Particle 
RT  Reverse Transcriptase 
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SINE  Short Interspersed Nuclear Element  
TE   Transposable Element 
TPRT   Target Primed Reverse Transcription 
TSD  Target Site Duplication 
UTR  Untranslated Region 
WB  Western Blot 
WT  Wild- Type 
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INTRODUCTION 
1. TRANSPOSABLE ELEMENTS 
Transposable elements (TEs), also known as jumping genes, are repetitive 
genomic sequences able to move from site to site within the genome. Apart from rare 
exceptions, TEs have been identified in all organisms and comprise a high proportion of 
a species’ genome. For example, TEs occupy up to 85% of the Zea mays corn genome 
(figure 1) (Huang et al., 2012) and indeed it was in this specie that TEs were first 
discovered in 1950 by geneticist Barbara McClintock. In her seminal work, she revealed 
that distinct coloration of maize kernels was due to the excision of a transposon from a 
region encoding for an enzyme involved in pigmentation (McCLINTOCK, 1950).  
Owing to their mutagenic properties, TEs were believed to represent selfish DNA 
parasites, that exist merely to propagate themselves, representing a potential threat to 
genome integrity (Fedoroff, 2012). Nonetheless, the waves of transposon mobilization 
that occurred throughout evolution and the accumulation of TE-derived sequences in the 
genome suggest that TEs could provide an inheritable and powerful source of genomic 
plasticity and regulation, as proposed since the beginning by McClintock. To further 
support this idea, over the last two decades, increasing evidence has shown that, 
although most transposable elements have lost their activity during evolution, the 
remaining subset continues to move both in the germline and in adult somatic tissues 
(Richardson et al., 2015). Although functional roles and mobilization mechanisms 
remain poorly understood, it is now clear that TEs coevolved with their host genomes. 
Indeed cells developed defenses from TE uncontrolled genomic expansion but, at the 
same time, took advantage of TE domestication.  
Overall, ongoing TE mobilization is still impacting structure and functions of 
most eukaryotic genomes, thus creating important levels of intra- and inter-individual 
genomic variability. 
According to their mechanism of mobilization, termed transposition, mammalian 
transposable elements are classified in two main groups: class I or retrotransposons, 
which mobilize via a RNA intermediate, using a copy-and-paste mechanism and class II 
or DNA transposons, which mobilize via a DNA intermediate, using a cut-and-paste 
mechanism (Wicker et al., 2007).  
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Figure 1. Transposons composition in different eukaryotic genomes. Pie charts show the abundance 
of each transposon type within the genome. The phylogenetic tree in the center describes evolutionary 
relationshops among species (from Huang et al.,2012). 
1.1 DNA transposons  
DNA transposons move within the genome by generating a DNA intermediate 
through the so called cut-and-paste mobilization mechanism: they are first excised from 
their original location and then reinserted elsewhere in the genome. Typically DNA 
transposons are composed of an open reading frame (ORF), encoding for the 
transposase enzyme, and are flanked by inverted terminal repeats (ITRs) (figure 2). In a 
round of transposition, the transposase recognizes ITRs and then mediates double strand 
excision and integration of DNA transposon into the new genomic location (Ivics et al., 
1997). For their mobilization, autonomous DNA transposons rely on their own 
transposase enzyme, whereas non autonomous elements take advantage of the 
transposase encoded by autonomous transposons. Upon insertion, target site 
duplications (TSDs) are generated at both ends of the “moved” DNA transposon and the 
size of the TSDs results to be unique for each different class of DNA transposon. Thus 
the “cut and paste” mobilization process consists of a non-replicative mechanism where 
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the DNA transposon is moved to a new location but no transposon copies are generated, 
although few exceptions are represented by Helitron and Maverick transposons which 
are replicated and do not induce double strand breaks during their insertion (Muñoz-
López and García-Pérez, 2010). DNA transposons are active in many species (i.e. P-
elements in Drosophila, Activator-Dissociation elements in maize and PiggyBac from 
cabbage looper moth) (Richardson et al., 2015), however, in mammals, with the 
exception of bats, they had a limited life span owing to their mutagenic potential. 
Indeed during evolution they have largely accumulated mutations which rendered them 
immobile. Computational analyses indicated that DNA transposons activity ceased in 
the primate lineage at least 37 million years ago (Pace and Feschotte, 2007). 
Approximately 3% of a typical mammalian genome is composed by DNA transposons 
(Beck et al., 2011; Keane et al., 2014; Lander et al., 2001; Mouse Genome Sequencing 
Consortium et al., 2002).  
 
 
Figure 2. Structure of DNA transposons. DNA transposons have flanking inverted terminal 
repeats (ITRs) and a unique open reading frame encoding for transposase (Martens et al., 2005). 
1.2 Retrotransposons 
Retrotransposons represent the predominant class of TEs in most mammalian 
genomes, accounting for up to 40% of human and mouse genomes (Lander et al., 2001; 
Mouse Genome Sequencing Consortium et al., 2002). They duplicate themselves via a 
RNA intermediate using a copy-and-paste mechanism: retrotransposons are first 
transcribed to an RNA copy and then reverse transcribed and inserted in a new genomic 
location. In this way, a second novel insertion is created, while the original transposon 
is preserved. Unlike DNA transposons, particular subsets of retrotransposons retained 
their transposition activity in mammalian genomes. 
Depending on the presence of long terminal repeats (LTRs) at their extremities, 
retrotransposons can be classified in LTR and non-LTR retrotransposons (Crichton et 
al., 2014). As for DNA transposons, retrotransposons can self-mobilize using the 
transposition machinery autonomously encoded (autonomous retrotransposons) or they 
can be mobilized relying upon the proteins encoded by other elements (non autonomous 
elements) (Cordaux and Batzer, 2009).  
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LTR retrotransposons 
Approximately 10% of a typical mammalian genome is made of long terminal 
repeat (LTR) retrotransposons (Lander et al., 2001; Mouse Genome Sequencing 
Consortium et al., 2002). In terms of structure these elements share features similar to 
those of retroviruses but they have lost their inter-cellular mobilization capability, 
therefore they are also called endogenous retroviruses (ERVs). A canonical full length 
LTR retrotransposon presents 5’ and 3’ LTRs along with gag, env and pol sequences 
(figure 3). In general, LTR retrotransposons contain functional gag and pol genes that 
encode for proteins and enzymes involved in retrotransposition, but lack a functional 
envelope (env) gene. Sometimes, the recombination between LTRs eliminate 
completely env gene, generating “solo LTRs” (Mager and Stoye, 2015). The absence of 
a functional env gene relegate ERVs to an intracellular life.  
Most mammalian LTR retrotransposons underwent a massive accumulation of 
mutations that made them immobile, especially in the human genome. Nonetheless in 
mouse, ERV insertions are responsible for almost 10% of spontaneously occurring 
mutations. Murine active ERVs include both autonomous elements, such as 
intracisternal A-particles (IAPs) and MusD elements, and non-autonomous 
retrotransposons, such as early transposons (ETn) and mammalian apparent LTR 
retrotransposons (MALRs) (Maksakova et al., 2006).  
 
 
Figure 3. Structure of the major mammalian LTR retrotransposons. Main classes of LTR 
retrotransposons present in human and mouse genomes are given by IAP and HERV elements. 
Transcriptional regulatory regions are indicated with filled rectangles. Transcription start sites are 
depicted with arrows. Main protein coding regions are shown with open rectangles. LTR, Long terminal 
repeats (Crichton et al.,2014). 
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Non-LTR retrotransposons 
Non autonomous elements 
Non autonomous elements mobilize by using in trans the retrotransposition 
machinery encoded by autonomous elements (generally LINE1s). The most abundant 
class of non autonomous elements is represented by Short Interspersed Nuclear 
Elements (SINE) that constitute about 10% of the sequenced mammalian genome. They 
originate from small RNApol III transcripts, including tRNAs and the 7SLRNA 
component of the signal recognition particle (Crichton et al., 2014). Since their 
insertions can occur both in gene deserts and in gene rich regions, SINE elements 
represent a major source of genomic variability and provide regulatory elements for 
gene expression (Carrieri et al., 2012; Elbarbary et al., 2016). However in the less 
fortunate cases, SINE insertions can be associated with diseases (Hancks and Kazazian, 
2012).  
In humans, the most abundant SINEs are SVA and Alu elements. SINE-
R/VNTR/Alu elements or SVA (~2 kb sequence) are the youngest human 
retrotransposons and account for about 0.2% of the human genome (Hancks and 
Kazazian, 2012). They are composed of a hexameric repeat region, followed 
sequentially by an inverted Alu-like sequence, a variable number of tandem repeats 
region, a HERV-K10-like region (SINE-R) and a polyA tail of variable length (figure 
4). Apparently SVA elements do not contain internal promoter; nevertheless they are 
transcribed by RNA polymerase II and the resultant RNA transcript is presumably 
trans-mobilized by the L1-encoded proteins (Beck et al., 2011,Cordaux and Batzer, 
2009). Alu elements ( ̴ 300bp) represent almost 11% of the human genome and typically 
exhibit a dimeric structure with a left monomer separated from the right monomer by an 
A-rich linker region (figure 4). The 5’end contains an internal RNA polymerase III 
promoter (A and B boxes) and the element ends with a polyA tail of variable length. As 
Alu elements do not contain any RNA polymerase III terminator, their transcripts extend 
into the downstream flanking sequence until a terminator is found (Richardson et al., 
2015). The counterpart of Alu elements in mice is given by B1 elements (~140 bp) that 
accounts for roughly 550,000 copies in the mouse genome (approximately 2,7% of 
mouse DNA) (Ponicsan et al., 2010). Like Alus, they derive from a 7SL RNA precursor 
and present an internal RNA pol III promoter composed of A and B boxes and terminate 
with a polyA tract that is flanked by genomic DNA containing an RNA pol III 
terminator; but unlike Alus, mouse B1s have a monomeric structure (figure 4).  
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B2 elements (~200 bp) are a second class of tRNA-derived murine SINEs that 
account for about 300,000 copies in mouse genome. Their structure is similar to B1s 
and they are transcribed by RNA pol III, as well (figure 4).  
In addition, the transposition machinery encoded by autonomous elements 
occasionally trans-mobilizes mature cellular RNAs, like housekeeping genes mRNAs, 
ribosomal protein encoding genes, uracil-rich small nuclear RNAs and small nucleolar 
RNAs (Garcia-Perez et al., 2007; Weber, 2006). This process leads to the formation of 
processed pseudogenes that are scattered throughout the genome (figure 4). In some 
cases, processed pseudogenes can develop new cellular functions providing cells with 
new adaptive tools. 
Autonomous elements 
Long interspersed nuclear elements (LINE) are autonomous non-LTR 
autonomous retrotransposons that are highly abundant in mammalian genomes. They 
include LINE1, LINE2 and LINE3 subfamilies but among these, only LINE1 (or L1 
elements) maintained mobilization capabilities in humans and mice (Lee et al., 2007). 
Being currently active in the mammalian genome and being able to mobilize both 
autonomous and non autonomous retrotransposons, L1s can significantly impact many 
biological processes of a L1-harboring cell. 
The abundance, structure and properties of mammalian L1 elements will be 
extensively described in the next paragraph, with a particular focus on murine L1s. 
 
 
Figure 4. Structure of the main human and mouse non LTR retrotransposons. Each class of 
non LTR in human (left) and mouse (right) genome is listed with its name. Arrows depict transcription 
start sites. Structural components of each element are enclosed in rectangles. Detailed description of 
every retrotransposon type is in text (Richardson et al.,2015).  
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1.3 L1 retrotransposons 
L1s constitute approximately 17% of the human genome and 19% of the mouse 
genome (Mandal and Kazazian, 2008). Most L1s are retrotransposition-defective owing 
to 5’ end truncation, internal rearrangements or point mutations that disrupt their open 
reading frames. Nonetheless, a portion of L1s in both human and mouse genomes are 
full length elements, potentially able to mobilize. Among the 5,000 L1 full length 
copies present in the human genome, roughly 80-100 elements contain two intact open 
reading frames and are retrotransposition-competent (Beck et al., 2011). By comparison, 
the mouse genome contains about 11,000 L1 full length copies, of which at least 3,000 
are still active (Goodier et al., 2001).  
Full length L1 elements are ~6kb sequences composed by a 5’ untranslated region 
(UTR), two open reading frames (ORF1 and ORF2) and a 3’UTR followed by a 
polyadenylation signal (AATAAAA) (figure 4).  
The 5’UTR region houses an internal RNA polymerase II sense strand promoter 
that in humans also display antisense properties (Speek, 2001, Mätlik et al., 2006). 
5’UTR is followed by ORF1 and ORF2 that encode for the proteins required for L1 
retrotransposition (Moran et al., 1996). ORF1 encodes for a 40kDa protein (ORF1p) 
having RNA-binding and chaperone activities (Martin, 2006). ORF1p contains a highly 
conserved C-terminal region, an RNA binding motif and a less-conserved N-terminal α-
helical domain (Ostertag and Kazazian, 2012). ORF2 encodes for a 150 kDa protein 
(ORF2p) with three conserved domains, an N-terminal endonuclease (EN) domain, a 
central reverse-transcriptase domain (RT) and a C-terminal zinc knuckle-domain 
(Doucet et al., 2010). The L1 EN domain is responsible for the dsDNA nick at the target 
insertion site, whereas the RT activity generates the cDNA copy of L1 to be inserted 
into the new genomic location (Feng et al., 1996; Mathias et al., 1991, Beck et al. 2011; 
Ostertag and Kazazian, 2001). The 3’UTR of L1 contains a functional but weak 
RNApol II polyadenylation signal near the 3’end. Signs of promoter activity residing on 
the 3’UTR of both human and murine L1s have been recently reported (Faulkner et al., 
2009). 
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Mouse L1 elements 
The sequence length of a full length mouse L1 element can vary between 6kb up 
to 8kb (Sookdeo et al., 2013). These differences are due to the presence of a variable 
region located in the 5’UTR of mouse L1s, which contains tandem repeats of 200 bp, 
named monomers, followed by a short non-monomeric linker region right upstream of 
the ORF1 sequence (figure 5). The monomers at the 5’UTR differ in their number and 
sequence among different L1s. According to the organization of monomers at the 
5’UTR, murine L1s can be divided into subclasses. Phylogenetically, all mouse L1 
subtypes seem to derive from a common ancestor but during evolution older L1 
elements accumulate more mutations and are more divergent than young L1s (Adey et 
al., 1994). At least three groups of monomers have been identified: V, F and A subtypes 
(Goodier et al., 2001). The most ancient V family is not very abundant and lacks the 
5’end therefore accounting only for inactive elements (Adey et al., 1994). The A family 
members contain monomer repeats of 208bp at their 5’ region and include about 6,500 
full length elements. A small subset of them (~900) are supposed to be active because 
they contain intact ORF1 and ORF2 and they are transcribed (Severynse et al., 1992). 
The F-lineage was recently been discovered to comprise new young, transcriptionally 
active L1 families: the Tf and Gf L1 subtypes. Likely, these two families derive from a 
common ancestor, but during evolution, they have diverged in their 5’UTR monomeric 
sequence. In terms of abundance, Tf subfamily has 1800 potentially active elements 
among 3000 full length members (Naas et al., 1998), whereas the most recently 
discovered Gf type includes 400 active elements among 1500 full length members 
(Goodier et al., 2001).  
In vitro experiments aimed to test the activity of the mouse Tf 5’UTR monomers 
have revealed that the promoter activity lies within the monomers and it seems to be 
enhanced proportionally to the number of monomers (DeBerardinis and Kazazian, 
1999). Hence, the acquisition of new promoter sequences seems to lead to evolutionary 
success. 
Concerning murine L1 ORF1 sequence, it displays trimeric organization having a 
coil coiled (CC) domain at the 5’end, followed by RNA-recognition motif (RRM) and a 
C-terminal domain (CTD). RRM and CTD domains are well conserved across L1 
subfamilies whereas the CC domain, involved in trimerization of ORF1p, presents 
relevant levels of structural variation. Notably, a functional antisense RNA pol II 
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promoter, residing in mouse L1 ORF1 sequence, has been recently identified (Li et al., 
2014).  
The second open reading frame, ORF2, is the most conserved region among the 
different murine L1 subfamilies, showing very few amino acid changes, indicator of 
strong purifying selection on this sequence. By contrast, the 3’UTR includes the highest 
number of variable sites within murine L1 regions (Sookdeo et al., 2013).  
Within the mouse genome, L1s are non-randomly distributed. Tipically, L1s are 
more abundant in AT-rich and gene-poor regions of the genome (Boyle et al., 1990), 
suggesting that possible deleterious effects of L1 insertion within gene bodies have been 
strongly discouraged during evolution. Nonetheless, when L1 insertions occur close to 
genes or even within them, the host gene expression can be consequently modulated 
(Han et al.,2004, Muotri et al, 2005). Notably, L1 localization depends also on L1 age, 
with younger L1s found in closer proximity to genes than older ones. Moreover, recent 
insertions tend to fall in preferential genomic regions, arising the concept of “hotspot” 
of retrotransposition within the genome (Jachowicz and Torres-Padilla, 2016). 
Additionally,intergenic L1 distribution are more frequent in autosomes and X 
chromosomes, whereas a greater intragenic density was reported in Y chromosome 
(Ngamphiw et al., 2014).  
Importantly, a certain degree of variability in genomic L1 repertoire between 
inbred mouse strains has been described. A comprehensive study of intermediate length 
structural variants evidenced a high degree of polymorphisms at sites of integration of 
both L1s and non-autonomous retrotransposons. Moreover this study showed that L1 
integrants can be either sense or antisense oriented (Akagi et al., 2008). A complete and 
updated summary of genomic rearrangements in mouse species is provided by 
MouseIndelDB (Akagi et al., 2010). 
Altogether, this evidence shows the presence of ongoing endogenous L1 
mobilization in mice. This phenomenon possibly leads to important inter-individual 
differences in L1 copy number and transcriptional variations in murine genomes.  
  
Introduction 
 
14 
 
 
 
Figure 5. Structure of a full length murine L1. Mouse L1 is a ~7kb sequence composed of a 
5’untraslated region (UTR), two open reading frames, a 3’UTR and a polyadenylation (pA) tail. L1 
element is flanked by target site duplications (TSD) of the insertion site. The 5’UTR region is composed 
of a variable number of  ̴200 bp monomers, depicted with orange triangles. ORF1 encodes for the RNA-
binding protein ORF1p. ORF2 encodes for ORF2p protein, having endonuclease (EN) and reverse-
transcriptase (RT) activities. Black arrows indicate sense and antisense promoters. Dashed arrows show 
additional putative promoter in the 3’UTR.  
2. L1 RETROTRANSPOSITION 
L1 elements have shaped and greatly expanded mammalian genomes through at 
least two mechanisms: their self-retrotransposition and their ability to provide the 
machinery for the transposition of other mobile elements. The study of L1 structure has 
elucidated many aspects of the mechanism of L1 retrotransposition, a multi-step process 
that ultimately results in a de novo insertion.  
2.1 Molecular mechanism of retrotransposition  
The L1 mobilization process starts with the transcription by RNA polymerase II 
of a genomic L1 sequence from its own internal promoter that generates a bicistronic 
mRNA. The L1 mRNA contains a polyA tail which can be encoded by its own 
polyadenylation signal or a downstream signal. Whether L1 transcripts contain a 7-
methylguanosine cap remains unknown (Ostertag and Kazazian, 2001). After 
transcription the L1 mRNA exits the nucleus through an unidentified mechanism and, 
once in the cytoplasm, ORF1 and ORF2 proteins are translated and bind to an mRNA 
molecule (figure 6). These two proteins show strong cis-preference, so that they 
preferentially associate with their own L1 mRNA, to form a ribonucleoprotein particle 
(RNP) (Doucet et al., 2010; Hohjoh and Singer, 1996; Kulpa and Moran, 2006; Martin, 
1991). The formation of the complex is believed to involve multiple copies of ORF1p 
and only few copies of ORF2p (Beck et al., 2011). Interestingly, ORF1p, ORF2p and 
L1 RNA have been shown to accumulate in cytoplasmic foci that are closely associated 
with stress granules proteins (Doucet et al., 2010; Goodier et al., 2007).  
Introduction 
 
15 
 
Then, through a mechanism yet poorly understood, which might involve active 
transport or nuclear membrane breakdown, the RNP is transported back to the nucleus. 
Here the integration of the L1 copy into the genome likely occurs via a process called 
target-site primed reverse transcription (TPRT) (figure 6). During TPRT the L1 
endonuclease recognizes the consensus sequence 5’-TTTT/A-3’ and catalyzes a single-
strand endonucleolytic nick in genomic DNA at the target site. The exposed 3’OH 
group is then used as a primer by the L1 reverse transcriptase ORF2p to synthesize a 
copy DNA (cDNA) of the L1 mRNA. Whether the L1mRNA acts only as a template or 
plays additional roles during TPRT remains still unclear (Feng et al.,1996, (Cost et al., 
2002). Then, the second-strand of the target-site is cleaved and used to prime the 
synthesis of the cDNA second strand, through a mechanism still poorly understood. 
Typical hallmarks of the integration process are the target-site duplications (TSDs), that 
are ~ 7-20 bp long sequences generated at each end of the L1 copy; the 3’ dA-rich tail 
of variable length, likely generated by the pairing of the A-rich sequence at the 3’end of 
L1 with the T-rich primer formed at the insertion site (Cordaux and Batzer, 2009, Sen et 
al., 2007).  
Notably, the vast majority of L1 insertion events lead to 5’end truncation on the 
L1 copy, probably due to the inability of L1 reverse transcriptase to copy the entire L1-
mRNA or to the action of cellular RNAse H which competes with L1 reverse-
transcriptase (Ostertag and Kazazian, 2001). As a consequence, the newly inserted L1 
copy lacks its promoter and is therefore unable to remobilize. The high frequency of 5’ 
end truncations resulting from new L1 retrotransposition events remains enigmatic but 
might reflect a first line of host defense against uncontrolled L1 mobilization (Beck et 
al., 2011). On average, in humans, the length of an inserted L1 is about one sixth of a 
full length element (Ostertag and Kazazian, 2001).  
Alternatively, to the canonical TPRT, L1 elements can also rely on a 
endonuclease independent (ENi) mechanism for their integration. This pathway likely 
represents a reminiscence of an RNA-mediated DNA repair mechanism and occurs 
when L1 uses pre-existing genomic double strand lesions to initiate TPRT (Eickbush, 
2002, Morrish et al.,2002). L1 elements integrated via the ENi mechanism display 
structural features distinct from those typical of TPRT-mediated L1 insertions, in that 
they generally lack TSDs, they are frequently 5’ and 3’ truncated and are often 
accompanied by the deletion of genomic DNA at the integration site (Morrish et al., 
2002). L1 integrants derived from ENi events have been observed in telomeres (Viollet 
Introduction 
 
16 
 
et al., 2014) but this process seems to be strongly discouraged in vivo (Babushok et al., 
2006)(Morrish et al., 2002).  
 
 
Figure 6. L1 retrotransposition cycle. A full length active L1 element is transcribed from its 
internal promoter to produce a bicitronic mRNA. L1-mRNA is then exported to the cytoplasm where 
ORF1 and ORF2 proteins are translated. ORF1 and ORF2 proteins can bind in cis to L1 mRNA or in 
trans to other cellular mRNAs to form the ribonucleoprotein (RNP) complex. The RNP complex then 
gains access to the nucleus, where the L1-RNA undergoes target site primed reverse transcription 
(TPRT). In TPRT a single strand nick is first made at the insertion site, then L1-mRNA is reverse 
transcribed and integrated into the new genomic location. Generally TPRT leads to 5’end truncation of 
the new L1 copy (Richardson et al.,2015). 
2.2 Molecular mechanisms influencing L1 retrotransposition 
Since L1 insertions and L1-mediated insertions might represent a significant 
threat to genome stability, host cells have developed a variety of mechanisms, at both 
transcriptional and post-transcriptional levels, to restrict L1 activity. Inhibition of 
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retrotransposition can occur through inter-correlated pathways, including epigenetic 
mechanisms (mainly DNA methylation and post-translational histone modifications on 
L1 promoter); premature polyadenylation; alternative splicing; small interfering RNAs 
and the activity of various cellular factors, some of which are typically involved in 
cellular defense against virus infection. 
Epigenetic silencing of L1 promoter 
Methylation of 5’ cytosine on CpG dinucleotides is a common mechanism of 
DNA methylation that leads to transcriptional silencing of the downstream gene. The 
presence of CpG rich regions in the L1-5’UTR sequence and their consequent 
methylation is associated with repression of L1 mRNA expression (Yoder et al., 1997). 
Typically, DNA methylation patterns are established in primordial germ cells and are 
then maintained throughout the entire life of an organism. De novo DNA methylation 
on L1 promoter can be carried out by DNA methyltransferases in germ cells. The 
deletion of de novo methyltransferase 3L (DNMT3L) gene in mouse germline leads to 
meiotic catastrophe, concomitant with extensive demethylation of L1 promoter region 
and aberrant overexpression of L1s and other transposons (Bourc’his and Bestor, 2004). 
Nonetheless, DNA methylation is thought to control L1 expression also in somatic 
tissues. In particular, demethylation of L1 5’UTR promoter and consequent L1 
activation can be provoked by the loss of methyl-CpG-binding protein 2 (MeCP2), a 
protein involved in global DNA methylation, primarily active in nervous tissues (Yu et 
al., 2001). MeCP2 knockout neural precursor cells and mice brains showed increased 
susceptibility for L1 retrotransposition. Accordingly, L1 promoter hypomethylation and 
abnormal L1 activity were reported in patients affected by Rett syndrome (RTT), a 
neurological disorder caused by a mutation in the MeCP2 gene (Muotri et al., 2010, 
2005).  
An alternative mechanism affecting the accessibility to L1 promoter during 
transcription is given by epigenetic modification on histone tails. Depending on which 
histone residue is modified, the output can be an increase or decrease of chromatin 
compactness around L1 promoter. Trimethylated lysine 9 on histone 3 (H3K9me3), an 
histone mark typically associated with repressed transcription, is largely present on L1 
promoter. This leads to a constitutive repression of full length L1 expression in normal 
conditions (Fadloun et al., 2013; Pezic et al., 2014). In mice, H3K9me3 is found across 
the entire L1-5’UTR sequence, including both monomeric and non-monomeric regions, 
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and co-localizes with the histone variant H2A.Z and the heterochromatin-binding 
protein HP1α (Rangasamy, 2013).  
Interestingly, during early embryogenesis (2-cell and 8-cell embryos), it has been 
shown that repressive H3K9me3 marks are consitutively present on L1 elements, 
whereas the deposition of active H3K4me3 can vary. The loss of H3K4me3 in 8-cell 
embryos consequently leads to L1 repression. This suggests that activation or silencing 
of L1 elements might be achieved by the modulation of activating marks, such as 
H3K4me3, rather than affecting constitutive repressive H3K9me3 (Fadloun et al., 
2013). Also H3K9me2 is associated with L1 sequences primarily in germ cells and its 
deposition is developmentally regulated (Di Giacomo et al., 2013).  
L1-RNA alternative splicing and premature polyadenylation 
L1 transcript maturation can be inhibited by alternative splicing. Indeed, human 
full length L1 RNA molecules contain a conserved donor splice site within the 5’UTR 
sequence. This splice site was revealed to be functional and its use leads to the 
generation of shorter L1 transcripts, that likely lost their mobilization properties 
(Belancio et al., 2008, 2006). Additionally, the interaction between hnRNPL, a protein 
involved in alternative splicing, and mouse L1 RNA (Peddigari et al., 2013) or human 
L1 RNPs (Goodier et al., 2013), suggest a further evidence for L1 retrotransposition 
modulation mediated by alternative splicing.  
Alternatively, L1 transcription can be influenced by premature polyadenylation. 
L1 elements are characterized by A-rich strands of variable length at their 3’region. This 
sequence contains both canonical and non-canonical polyadenylation (polyA) signals 
that can generate truncated L1 transcripts with compromised retrotransposition activity 
(Perepelitsa-Belancio and Deininger, 2003). Noteworthy, the presence of multiple 
polyadenylation signals might also contribute to fine–tune the expression of genes 
containing full length L1s (Han et al., 2004).  
Small interfering RNA-mediated L1 silencing 
Silencing of L1 retrotransposition by means of small interfering RNAs, 
particularly endogenous small-interfering RNAs (endo-siRNAs) and piRNAs, gives rise 
to another powerful cellular defense against L1 activation. Regarding endo-siRNAs, 
ongoing studies aim to elucidate the mechanisms by which they are generated and how 
they work to inhibit transposons. So far, it is known that endo-siRNAs are able to 
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repress L1 mRNA at a post-transcriptional level by promoting the disruption of the 
transposon transcript. They originate from a precursor dsRNA which is processed by 
Dicer proteins to form 21-24nt endo-siRNAs; these endo-siRNAs are then loaded by 
Argonaute proteins to form the RNA-induced silencing complex (RISC) that ultimately 
targets L1 mRNA for their cleavage (Levin and Moran, 2011). Precursor dsRNAs 
generating L1-specific endo-siRNAs can derive from the antisense promoter activity of 
L1-5’UTR (Yang and Kazazian, 2006) or from L1 mRNA itself. Indeed it was reported 
that L1-mRNA can be loaded by Microprocessor/Drosha siRNA machinery in vitro and 
this promote L1 RNA cleavage (Heras et al., 2013).  
Alternatively, L1 silencing can be induced by a specific class of small non-coding 
RNAs, the 26-31 nucleotide RNAs termed PIWI-interacting RNAs (piRNAs). PIWI (P-
element induced wimpy testes) proteins are a subclade of the Argonaute family, first 
discovered in Drosophila, that specifically binds to piRNAs in order to protect the 
genome of germ cells from the invasion of potential “genomic parasites”, such as 
transposons (Malone et al., 2009). Primary piRNAs originate from piRNA clusters, that 
are intergenic genomic loci encoding long precursor RNAs, and bind to PIWI proteins 
in the cytoplasm, in order to be processed and guided to their target transcripts. Once 
the piRNA recognizes the complementary L1-mRNA, two outcomes can follow: (i) 
disruption of the L1-mRNA similarly to what endo-siRNAs do, or (ii) production of a 
secondary piRNA, sense-oriented to the L1-mRNA that, in turn, targets antisense L1-
mRNA for the production of a new secondary antisense piRNA, able again to bind 
sense L1-mRNA for silencing. This gives rise to a cycle of rapid amplification of 
piRNAs known as “ping-pong cycle” (Ishizu et al., 2012). 
In mice, the PIWI clade proteins are represented by MILI, MIWI2 and MIWI 
(Kuramochi-Miyagawa et al., 2008). MILI binds primary piRNAs in the cytoplasm and 
targets them to the transposon mRNA to promote its cleavage for silencing or for the 
initiation of the “ping-pong” cycle (figure 7). MIWI2 loads secondary piRNAs in the 
cytoplasm and can either stoke the amplification cycle or translocate the piRNA-MIWI2 
complex to the nucleus to trigger DNA methylation on L1 transposon (Pillai and 
Chuma, 2012) (figure 7). Indeed, MILI and MIWI2 deficiencies in mouse 
spermatogonia induce the activation of L1 elements and this is accompanied with 
extensive demethylation on retrotransposon sequences, suggesting a role of these two 
factors in L1 promoter methylation (Aravin et al., 2008; Kuramochi-Miyagawa et al., 
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2008). MIWI contributes to transposon silencing by inducing L1 mRNA cleavage or 
translational repression (figure 7). 
 
 
Figure 7. MILI, MIWI2 and MIWI functions in piRNA pathway in germ cells. A) In piRNA 
biogenesis, MILI (orange) participates in the primary processing of primary piRNAs and then guides 
piRNAs to target mRNAs (green) to promote their cleavage or to initiate the “ping pong” amplification 
cycle (dashed circle arrow). MIWI2 (purple) binds secondary piRNAs during “ping pong” cycle to induce 
their maturation and/or translocate them into the nucleus for DNA methylation on target transposons B) 
piRNAs bound to MILI induce transposon silencing by cleavage of the transposon mRNA or potentially 
by inhibiting the translation of the transposon mRNA. piRNAs associated to MIWI2 promotes DNA 
methylation on transposon promoters for their silencing. MIWI (green), the third class of PIWI proteins, 
participates in transposon silencing by promoting mRNA cleavage and/or translation repression. (adapted 
from Pillai and Chuma, 2012).  
 
MILI and MIWI2 are particularly crucial during spermatogenesis, although they 
seem to play independent roles in piRNA biogenesis and DNA methylation. Indeed, in 
MIWI2 deficient mice L1 TE are derepressed, as expected, but “ping-pong” cycle 
activation can anyway take place. Moreover MILI is likely to control the expression of a 
larger subset of transposable elements than MIWI2, since MILI deficiency induces the 
expression of a larger repertoire of transposable elements and, at the same time, 
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promotes the DNA methylation on many more different transposons than MIWI2 
deficiency (Manakov et al., 2015). 
Surprisingly, very recent reports showed that piRNA pathway is functional not 
only in the germline. Indeed, piRNAs and MILI expression has been detected in adult 
brains of rodents and Aplysia (Ghosheh et al., 2016, Rajasethupathy et al., 2012). 
Moreover MILI deficient mice display hypomethylation of intergenic regions and L1 
promoters in the brain genome, suggesting that the roles of piRNAs in nervous tissues 
might be similar to those carried out in testes (Nandi et al., 2016; Pillai and Chuma, 
2012; Rajasethupathy et al., 2012)). 
Other cellular L1 restriction factors  
A number of transcription factors and cellular proteins involved in nucleic acid 
metabolism and DNA repair can contribute to restrict L1 retrotransposition. Among 
transcription factors able to bind L1 5’UTR and then regulate L1 transcription there are 
members of Sox and KRAB-zinc finger proteins. In particular, Sox2 can bind to Sox-
binding sites located in the L1-5’UTR promoter region and its expression inversely 
correlates with that of L1 elements (Muotri et al., 2005). The level of Sox2 association 
to L1-5’UTR correlates with the decrease of Sox2 expression across neuronal 
differentiation (Coufal et al., 2009). Alternatively, KRAB-associated protein 1 (KAP1) 
repressive complex can be recruited on L1-5’UTR by KRAB zinc finger proteins to 
repress L1 expression (Castro-Diaz et al., 2014; Jacobs et al., 2014). Notably, the 
ribosylation of KAP1, promoted by binding of SIRT6 to L1-5’UTR, facilitates KAP1 
interaction with HP1α and this leads to a heterochromatization of L1 promoter (Van 
Meter et al., 2014). 
Frequently, cells limit retrotransposon activity taking advantage of the innate anti-
viral immune response mechanisms. For example, deaminase proteins, tipically 
involved in innate response to retroviral infections, can act to inhibit also L1 
retrotransposons. Members of the APOBEC3 family as well as ADAR-1 deaminase are 
shown to robustly suppress L1 retrotransposition in cultured cells. Interestingly, ADAR-
1 directly interacts with L1 RNPs. However it remains yet poorly understood if L1 
inhibition requires or not the deaminase activity, that might influence for instance 
cDNA synthesis during L1-TPRT (Bogerd et al., 2006; Muckenfuss et al., 2006; 
Orecchini et al., 2016). Alternatively, overexpression of Trex-1, a DNA exonuclease, 
and SAMHD1, a tryphosphohydrolase that can decrease intracellular dNTPs 
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availability, is accompanied by repression of L1 retrotransposition in cultured cells 
(Stetson et al., 2008; Zhao et al., 2013). Moreover MOV10, an RNA helicase and 
component of RISC, able to prevent retrovirus replication, can inhibit retrotransposon 
activity, including human L1, Alu, SVA and mouse IAP elements and it can directly 
interact with L1-RNA in the L1 RNP, in cultured cells (Goodier et al., 2012). Similarly, 
in cultured human cells, RNAseL, an endoribonuclease that cleaves single-stranded 
RNAs, seems to be activated by double-stranded regions existing within L1-RNA or 
that originates from annealing to a complementary transcript generated by antisense L1 
promoter activity (Zhang et al., 2014). 
Finally, since L1 retrotransposition events via TPRT are prone to generate DNA 
double strand breaks (Gasior et al., 2006), it is reasonable that DNA repair pathways 
might influence L1 retrotransposition success. In this context, recent studies 
demonstrated that Ataxia telengectasia mutated (ATM) protein, a Ser/Thr kinase 
involved in DNA damage signaling, and excision repair cross-complementation group 1 
(ERCC1) proteins, a component of nucleotide excision repair (NER), can modulate L1 
retrotransposition (Coufal et al., 2011; Gasior et al., 2008).  
The extensive use of proteomics that is ongoing in these years allowed to identify 
a long list of host factors interacting with L1. However the effects on L1 
retrotransposition of most of these factors have not been determined yet (Goodier et al., 
2013; Moldovan and Moran, 2015; Taylor et al., 2013). 
3. L1 MOBILIZATION EFFECTS 
Fine-tuned L1 regulation is crucial for organismal biology. Several lines of 
evidence show that while elevated transposon expression is detrimental, some elements 
have also been recruited as new transcripts and/or proteins to benefit organismal 
function. From here derives a complex interaction between transposons and the host 
genome. Here it will be briefly described, from a molecular point of view, how L1-
retrotransposition events can create diversity through structural as well as functional 
changes in genome and transcriptome.  
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3.1  L1-insertional effects 
Genomic structural alterations 
L1-mediated retrotransposition events induce a variety of structural modifications 
in genome structure, including insertional mutagenesis, genomic rearrangements, 
mobilization of L1 flanking sequences and chromatin remodeling.  
o Insertional mutagenesis. When L1s are inserted in exons they induce 
interruption of the coding sequence. Owing to the immediate phenotypic effect, 
de novo L1 insertions causing insertional mutagenesis were the first to be 
detected and let us understand that transposable elements cannot be dismissed as 
mere “junk DNA”. In 1988 the group of Kazazian demonstrated for the first 
time that two independent mutagenic L1 insertions in the factor VIII gene 
caused hemophilia A in unrelated boys (Kazazian et al., 1988). The full length 
L1 precursor from which the disease-causing-L1 derived was then recovered 
from the genome of the mother of one of the two hemophilic patients 
(Dombroski et al., 1991). Since then L1s started to be studied with more 
attention.  
o Structural variations at the insertion site. Upon integration, L1 retrotransposition 
events can lead to genomic rearrangements at the target site through a variety of 
mechanisms. For example, the resolution of TPRT intermediates by single-
strand annealing or synthesis-dependent single strand annealing can lead to the 
formation of L1-mediated deletions or duplication at the insertion site. These 
processes likely involve the cellular repair machinery which recognizes and tries 
to repair the dsDNA nick caused by L1 during TPRT (Gilbert et al., 2005, 
Gilbert et al., 2002, Symer et al., 2002). From a genomic large-scale analysis it 
turned out that L1 insertions are frequently associated with structural 
rearrangements in human genomes (Beck et al., 2011). For example, the 
characterization of a deletion of 46kb in the PDHX gene, causing pyruvate 
dehydrogenase complex deficiency, led to the discovery of a full-length L1 
insertion between exon 2 and 10 of the gene, corresponding to the deleted region 
(Miné et al., 2007). Very recently, L1-insertion mediated deletions were 
observed also in healthy adult human brains (Erwin et al., 2016).  
o Nonallelic homologous recombination. Dispersed distribution of LINE and other 
repetitive sequences in the genome can lead to mispairing and consequent 
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nonallelic homologous recombination (NAHR) between them, thus producing 
structural variants. Alignment analysis of human and chimpanzee genomes has 
identified 55 cases of human-specific L1-NAHR associated deletions. In this 
mechanism, two pre-recombination L1s present in the chimpanzee genome have 
recombined via NAHR to generate the chimeric L1 in human genome (Han et 
al., 2005). The amount of structural variation caused by NAHR is significant and 
accounts for more than 0,3% of human genetic diseases (Belancio et al., 2008).  
o 3’ and 5’ transduction. Because in L1 elements canonical polyadenylation site is 
often bypassed on behalf of downstream signals, sequences flanking L1 3’ ends 
may be mobilized during L1 retrotransposition, a process termed 3’transduction. 
Transduction of 3’-L1 flanking sequences has been detected both in mouse and 
humans: through GenBank L1 database analysis, Goodier and colleagues have 
shown that 23% of 66 uncharacterized L1 sequences carried 3’flanking DNA 
with an average in length of 207 nucleotides and 3’transduction was more 
frequent in full-length L1 copies (Goodier et al., 2000). Similarly, 5’ 
transduction occurs when the promoter activity of a transcript initiating 
upstream to a L1 element is used to transcribe. 5’ transduction can be detected 
only by examining full length L1s, therefore its influence appears to be much 
less common than 3’ transduction (Beck et al., 2011). Through these two 
mechanisms, non-retrotransposon DNA located downstream or upstream of 
active L1s can be shuffled into new sites, thereby creating new genes. 
o Heterochromatization. L1 insertions seem to be able to alter chromatin state. 
This phenomenon was first hypothesized by M. Lyon after the observation of L1 
accumulation on X-chromosome, which led him to speculate that L1 might act 
as booster elements to promote the spreading of heterochromatin formation 
during X-inactivation (Lyon, 1998). This hypothesis was then demonstrated by 
experiments in ES cells that showed that L1s could have a dual role in 
nucleating heterochromatin formation on the inactive X chromosome. First, 
silent L1s, which are tightly packaged in heterochromatin, facilitate nucleation 
of a silent, heterochromatic compartment into which genes are recruited; second, 
a subset of active L1s, expressed during X-chromosome inactivation (XCI), 
participate in local propagation of XCI to certain genes that otherwise would be 
prone to escape silencing (Chow et al., 2010).  
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Alterations of cellular transcriptome 
Through their insertions, L1 elements can also contribute to modulating the 
transcriptome of the cell by providing new splice sites, adenylation signals and new 
promoters that can finally generate new reorganized transcription units. For example, 
when a L1 integrant falls into an acceptor splice site, it disrupts it and provokes exon 
skipping. On the other hand, if a new functional donor or acceptor splice site is added 
by L1 insertion, this leads to L1-exonization. Clearly, depending on the position of the 
splice site inside the L1 sequence, insertion of exonized L1s of different length might 
occur. In addition, truncated or rearranged L1s and antisense oriented splice sites can 
provide further sources of alternative splicing. As a consequence, the combinatorial 
usage of the numerous potential splice sites generated through L1 insertions adds 
complexity to the alternative splicing scenario of the cell, as confirmed by a screening 
analysis of a mouse cDNA library (Zemojtel et al., 2007).  
Otherwise, cellular transcriptome might also be affected by alternative promoters 
provided by L1s, highlighting a role for L1s as “portable promoters”. Functional 
sequences can derive from the sense canonical L1-5’UTR promoter of full length L1s 
and from 5’end truncated L1 fragments. In this context, Faulkner and colleagues 
unveiled a novel promoter sequence in the 3’UTR of L1s in both humans and mice. 
Moreover they showed that the canonical 5’UTR promoter of full length L1 elements is 
active in a tissue specific fashion, with higher activity in developmental and cancerous 
tissues (Faulkner et al., 2009). 
In humans, the antisense promoter (ASP) activity lying in the L1-5’UTR also 
plays a role in modulating cellular transcriptome. This emerged from studies in human 
embryonic stem cells and from analyses of expression profiles of chimeric mRNAs in 
different human tissues showing that L1-ASP is functional and can give rise to new 
transcription start sites for genes upstream of L1s on the antisense strand. Antisense 
promoter activity correlates with the one of the native promoter gene or can act in a 
tissue-specific manner, thus contributing to tissue-specific control of expression (Macia 
et al., 2011, Mätlik et al., 2006).  
Additionally, it has been shown that expressed L1s originate mostly from intronic 
L1s, suggesting that expression and insertion of L1s can act on transcriptional 
regulatory regions, such as enhancers or 3’UTRs, to modulate the expression of the 
hosting gene (Faulkner et al., 2009). 
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Recently, a new ORF has been discovered in the primate L1s, termed ORF0. This 
ORF is located upstream to L1-5’UTR in antisense orientation; it can be found in 
almost 3000 loci within human and chimpanzee genomes and it is functional. 
Additionally, since it contains two splice donor sites, ORF0 can also form fusion 
proteins with nearby exons. ORF0 seems favoring L1 mobility (Denli et al., 2015).  
Intriguingly, L1 insertions represent a major force in shaping the non-coding 
transcriptome in humans and mice. In these species more than 40% of long non-coding 
RNAs contain embedded transposable elements, including L1-derived sequences 
(Kapusta et al., 2013). 
3.2 L1 expression-mediated effects 
The retrotransposition of L1 elements can influence genomic stability and 
function upon insertion and through the expression of L1-mRNA and L1-encoded 
proteins. Overexpression of L1s has been linked to apoptosis, DNA damage and repair, 
cellular plasticity and stress (Goodier, 2016). For example, the production of L1-
ORF2p, not necessarily linked to a retrotranspositional event, can trigger DNA damage 
and provide a functional RT to cellular RNAs, thanks to its intrinsic EN and RT 
activities. As shown by immunostaining for γ-H2AX foci, L1 overexpression seems to 
induce large amounts of DNA double strand breaks in cultured cells (DSBs) (Erwin et 
al., 2016; Gasior et al., 2006). The high levels of DSBs exert cellular toxicities that 
eventually lead to cell cycle arrest, apoptosis and cellular senescence of L1 
overexpressing cells (Belancio et al., 2010; Belgnaoui et al., 2006). The induction of 
DNA DSBs can be clearly ascribed to the endonuclease domain of ORF2p. However, 
although to a lesser extent than compared to EN domain, also mutations in the RT 
domain of ORF2p can modulate cell viability (Wallace et al., 2008). How the RT 
domain might be detrimental for cells remains largely unclear. According to a model, 
the interaction of L1 RT and random genomic breaks, occurring for instance during 
endonuclease-independent integrations (Morrish et al., 2002, Sen et al.,2007), could 
inhibit DNA repair. Noteworthy, the mobilization of SINE elements do not necessarily 
require an entire L1 RNP but can rely on the production of only a functional L1-ORF2p 
(Dewannieux et al., 2003). Therefore, the expression of both full length and truncated 
L1 retrotransposons can affect the host genome. 
Concerning L1 transcripts, as already described previously, L1-mRNA might be 
the source of cellular piRNAs and endo-siRNAs, therefore contributing to gene 
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transcriptional regulation and chromatin remodeling. Notably, from the analysis of 
CAGE tags of both human and mouse transcriptomes, it emerged that L1-derived 
transcripts display a prevalent nuclear localization, therefore suggesting their potential 
role in association with nuclear non-coding RNAs (Faulkner et al., 2009). Furthermore 
it has been proposed that actively transcribed L1s might help the spreading of repressive 
Xist-dependent domain during X chromosome inactivation (Chow et al.,2010).  
Hence, whether L1 expression has a role for the host organism or represents 
merely “transcriptional noise” seems to strongly depend on the context in which it takes 
place and it is nowadays under intense investigation. As it will be described in the next 
chapters, L1 expression seems to occur in precise temporal and spatial windows. This 
suggests that this phenomenon requires a strict control by the host cell, since it can 
provide evolutionary advantages for the host organism, but it can also entail pathology 
onset. 
4. GERMLINE L1 RETROTRANSPOSITION 
The accumulation of L1 elements in the genome during evolution of eukaryotes is 
a clear sign of heritable retrotransposition events occurring in germ cells during 
gametogenesis (figure 8). Plenty of data shows that L1 retrotransposition largely occurs 
in the germline. High levels of L1 expression was found in these cells in mammals: 
increased levels of full length L1 mRNA and L1 proteins were originally detected in 
leptotene and zygotene spermatocytes and this expression seems to be lost during 
development (Trelogan and Martin, 1995, Branciforte and Martin, 1994). Additionally, 
by taking advantage of L1 transgenic mice harboring an engineered human L1 element 
under the control of its endogenous promoter, L1 retrotransposition events were 
detected in male germ cells while L1 expression is restricted to testis and ovary 
(Ostertag et al., 2002). Furthermore, expression of L1-RNA was shown to be high in 
mouse full grown oocytes (Peaston et al., 2004) and L1 reverse transcriptase activity 
was detected in mature spermatozoa (Vitullo et al., 2012).  
Germline L1 activation reflects the distinctive pattern of DNA hypomethylation 
typical of germ cells, where epigenetic patterns has to be flexible to permit cellular 
specification and differentiation (Smallwood and Kelsey, 2012). Not surprisingly, the 
tight control of L1 expression in germ cells is achieved by multiple epigenetic 
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pathways, including de novo DNA methylation, piRNA pathway and chromatin 
remodeling (Bourc’his and Bestor 2004, DiGiacomo et al.,2013).  
Interestingly, a recent study conferred a functional role to L1 retrotransposons in 
the process of fetal oocyte attrition (FOA) in mice. FOA is the process of elimination of 
most meiotic prophase I (MPI) oocytes before birth. Increased levels of L1 expression 
and nuclear accumulation of L1-ORF1p associate with enhanced MPI defects, FOA, 
oocyte aneuploidy and embryonic lethality. On the other hand, reverse transcriptase 
inhibitors considerably affect FOA dynamics and meiotic recombination, suggesting an 
RT-dependent pathway for L1 implication in oocyte elimination in MPI. They propose 
that in FOA mechanism the oocytes with less L1 activity are favored, since they 
represent a lower risk for future generations (Malki et al., 2014).  
 
 
Figure 8. Effects of germline retrotransposition. Retrotransposition of L1 elements occurs in the 
germline and thus creates population variants that are present in every cell of an individual’s body and are 
passed on future generations (Erwin et al.,2014) 
5. SOMATIC L1 RETROTRANSPOSITION  
Although originally thought to occur only in the germline, L1 retrotransposition is 
emerging having a major role in shaping genomes and reconfiguring gene expression 
networks in somatic cells. Notably, L1 integrants resulting from somatic 
retrotransposition events are not incorporated into germ cells, so they are not heritable 
and will not accumulate in the genome of all cells of an individual. This leads to the 
formation of genomic diversity between the cells of a somatic tissues, an event known 
as somatic mosaicism. The best characterized example of somatic mosaicism is the one 
creating VDJ recombination in B lymphocytes, aimed at providing a defense against the 
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variety of natural pathogens. Afterwards, the use of whole genome sequencing 
screenings allowed detecting many other cases of genomic variants in somatic tissues of 
an individual. Notably, a substantial portion of these variations arose from L1 
retrotransposition events (Lupski, 2013). So far, early embryos, cancer and the brain 
have been described as particularly fertile soils for somatic L1 activity, thus 
representing typical examples of L1-derived genomic mosaics. Here will be described 
up-to-date knowledge of somatic L1 retrotransposition in early embryos and in the 
brain. 
5.1 L1 retrotransposition in the early embryo  
In 2009, Kano and colleagues demonstrated for the first time that L1 
retrotransposition can occur in early embryos. In particular, they detected high levels of 
L1-mRNA in mouse pre-implantation embryos and showed that L1 integration is likely 
favored during embryogenesis. To demonstrate this activity, they created a transgenic 
mouse model harboring a L1 retrotransposition cassette where the L1 element is 
controlled by its endogenous promoter and is interrupted by an intronic sequence. 
According to this strategy, PCRs using intron-flanking primers allowed to distinguish 
the L1 transgene from a L1 retrotransposed copy since intron removal can occur only 
upon L1 retrotransposition. Interestingly, the comparison of L1 integrants in different 
developmental stages revealed that L1 retrotransposition events are more frequent in 
embryos (blastocyst and E9.5) than in spermatogenic fractions (Kano et al., 2009).  
Consistent with previous observations, another study showed that mouse early 
embryos physiologically contain abundant L1 mRNAs and dynamic expression of L1 
retrotransposons occurs during embryo maturation (Fadloun et al., 2013).  
Moreover a significant increase in L1 copies was registered in genomic DNAs 
derived from mouse zygotes and 2-cell embryos as compared to sperm and oocytes, 
suggesting active integration in this developmental window (Vitullo et al., 2012). 
Accordingly, the same group showed that L1-RT plays a crucial role in early embryo 
development: inhibition of RT leads to an arrest of development at the two- and four-
cell stage (Beraldi et al., 2006; Pittoggi et al., 2003).  
In humans, a X-linked L1 insertion responsible for choroideremia eye pathology 
displays somatic and germ-line mosaicism in the mother of the affected patient, 
suggesting that L1 insertion can occur very early in human embryonic development 
(van den Hurk et al., 2007).  
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Indication of a good tolerance of L1 retrotransposition in early embryos is 
suggested also by the high expression of L1s and the accumulation of new L1 insertion 
reported in human pluripotent stem cells and embryo stem cell lines (Garcia-Perez et al., 
2007; Klawitter et al., 2016; Marchetto et al., 2013; Wissing et al., 2012, 2011).  
Clearly, the fact that the de novo L1 insertion is incorporated in the pluripotent 
stem cell genome, before or after germline specification, defines its hereditability 
(figure 9). However, the frequency and the specific timing of endogenous L1 
retrotransposition across development have not been fully described.  
 
 
Figure 9. Effects of retrotransposition in early embryos. Retrotransposition of L1 elements 
occurring in pluripotent cells of the early embryo can have three outcomes. If pluripotent cells harboring 
de novo L1 insertions differentiate into germ cells as well as somatic cells (A.), or only into germ cells 
(B.) or only into somatic cells (C.), they will contribute, respectively, to germline together with somatic 
mosaicism (A.), only germline (B.) or only somatic mosaicism (C.) within an individual. Germline 
insertions can be consequently passed on future generations (Richardson et al.,2015).  
5.2 L1 retrotransposition in the brain  
The brain is composed of a heterogeneous population of cells having peculiar 
functional and structural features, even within cells of the same subtype. Plenty of data 
now shows that part of this variability might derive from L1 mobilization events 
occurring in this organ (figure 10). Both engineered and endogenous L1s have been 
shown to mobilize in the mammalian brain. The first evidence for this came from the 
Gage laboratory when it was shown that the differentiation of adult rat hippocampal 
neural stem cells into neuronal precursor cells (NPCs) and neurons leads to an increase 
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in L1 transcript levels and that an engineered L1 element can undergo retrotransposition 
in cultured rat NPCs (Muotri et al., 2005). Later, L1 retrotransposition was reported also 
in embryonic stem cells derived from neuronal progenitors (Coufal et al., 2009). More 
recently, it has been shown that also mature neuronal cells differentiated from human 
embryonic stem cells (hESC)-derived NPCs contain high levels of L1 mRNA and can 
support L1 genomic integration of an engineered L1 element (Macia et al., 2016).  
As previously mentioned, Sox2 can regulate L1 transcription and consequent 
retrotransposition in rat hippocampal neural stem cells. Alternatively, activation of L1 
retrotransposition in neural precursor cells could arise from DNA methylation 
permissive patterns, where MeCP2 plays a crucial role, or from an alteration in DNA 
repair cellular machinery, as shown in the case of reduced kinase activity of Ataxia 
Telengectasia Mutated (ATM) (Muotri et al. 2005, Coufal et al.,2009, Macia et al.,2016, 
Coufal et al.,2011). All these data were then confirmed according to a model of L1 
retrotranposition control where the activation of L1 retrotransposons corresponds to the 
progression from neural stem cell to neural progenitor (Erwin et al., 2014; Muotri et al., 
2010).  
In line with in vitro experiments, L1 retrotransposition events were also reported 
in vivo. These studies took advantage of L1-EGFP-transgene where the EGFP reporter 
is interrupted by an intron and is controlled by CMV promoter and inserted in opposite 
orientation in the 3’UTR region of a human L1. By this approach, L1 retrotransposition 
events were revealed in the brain occurring during the first phases of neurogenesis, 
particularly between E8.5 and E10.5 (Muotri et al. 2005). In addition, it was recently 
reported that L1 copy number is increased in the adult mouse hippocampus, a 
preferential site of adult neurogenesis in mammalian brains (Ueno et al., 2016).  
Similarly, increases of genomic L1 copies that likely derived from somatic L1 
retrotransposition were detected also in human adult hippocampus. Using a Taqman-
qPCR approach on genomic DNA extracted from bulk tissue, Coufal et al. performed a 
relative quantification of L1-ORF2 sequences in different somatic tissues, showing that 
approximately 80 more L1 copies were present in the human hippocampus when 
compared to other non-nervous tissues, like heart and liver, taken from the same 
individual. Notably this experiment evidenced significant levels of genomic variability 
between different brain regions within an individual and between different individuals 
(Coufal et al., 2009).  
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In line with these results, the use of next-generation sequencing further confirmed 
the occurrence of somatic L1 retrotransposition in human brain genomes. Baillie et al. 
developed a retrotransposon-capture sequencing (RC-Seq) technique, which is able to 
enrich sequencing libraries for fragments containing L1-genomic junctions. With this 
technology, they demonstrated that 7743 putative new L1 somatic insertions were 
present in the hippocampus and caudate nucleus of three individuals, supporting the 
idea of somatic mosaicism in the brain (Baillie et al., 2011). 
Consistent with these data, high levels of L1 mRNA were detectable in brain 
tissue samples compared to several other somatic tissues (Belancio et al., 2010) and the 
analysis of CAGE (Cap-analysis gene expression) tags on human and mouse 
transcriptome revealed that L1s are extensively expressed in the brain (Faulkner et 
al.,2009).  
However, the analysis of bulk tissue, though being highly informative, carries 
limitations in the detection of L1 retrotransposition events occurring in a small subset of 
cells within the entire tissue. Therefore, the employment of single cell approaches is 
now trying to better assess the extent of neuronal L1 retrotransposition. A first single-
cell genomic study performed on whole cell amplified genomic DNA from 300 single 
neurons of cerebral cortex and caudate nucleus estimated the frequency of unique 
somatic L1 insertion around 0.6 per neuron (Evrony et al., 2012). Two subsequent 
studies evaluated different rates of genomic L1 insertion in neurons of human 
hippocampus as well as frontal cortex: Upton and colleagues showed an average of ~13 
L1 insertion events per hippocampal neuron, whereas Erwin and colleagues estimated 
0.58-1 somatic L1 insertion events per neuron in hippocampus and frontal cortex (Erwin 
et al., 2016; Upton et al., 2015).  
Overall, although the exact L1 retrotranspositional rate per neuron needs to be 
refined and likely varies in different brain regions and cell types, it is now clear that the 
mammalian brain represents a somatic mosaic resulting from active L1 
retrotransposition.  
Notably, the mobility of transposable elements has been also detected in the 
Drosophila brain (Li et al., 2013; Perrat et al., 2013), indicating its conserved feature 
throughout evolution and raising the hypothesis that mobilization of TEs could have a 
functional role in normal brain physiology.  
Conversely, the perturbation of this mechanism can be associated with 
neuropathology, as described with some examples in the next paragraph. 
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Figure 10. Effects of somatic L1 retrotransposition in adut brain. Somatic retrotransposition 
increases as neural stem cells differentiate into neurons and results in neurons with unique genomes (blu 
and red). Variability exists between the rates of retrotransposition and regions in which it occurs between 
individuals. High rates of retrotransposition events seem to occur in the hippocampus and frontal cortex 
in humans (Erwin et al.,2014).  
L1 retrotransposition and neurological diseases 
The insertion of L1 elements in intragenic regions with the consequent disruption 
of the targeted gene function has been associated with several diseases, as extensively 
described in many reviews by Kazazian and Hancks (Hancks and Kazazian, 2016, 
2012). However, several pathologies, including many neurological diseases, correlate 
with deregulation of L1 retrotransposition.  
In particular, it has been shown that iPS cells from patients affected by Rett 
Syndrome (RTT), a neurodegenerative disorder caused by a mutation in the X-linked 
MeCP2 gene, present an increased susceptibility to L1 retrotransposition while MeCP2 
knockout mice display enhanced L1 transcription and retrotransposition (Muotri et al., 
2010).  
Additionally, unregulated L1 mobilization has been reported in Ataxia 
telengectasia, a neurodegenerative disorder caused by mutations in the ATM gene that 
is involved in DNA double strand break signaling. Cells lacking ATM show increased 
retrotransposition of an engineered human L1 element and postmortem brains of ATM 
patients present an increased genomic L1 content (Coufal et al., 2011).  
Furthermore, a higher L1 copy number was found in the pre-frontal cortex 
neurons and iPS cells of patients affected by schizophrenia (Bundo et al., 2014). 
Altogether, these findings highlight a correlation between enhanced L1 activation 
and neuropathology. The triggering event and the consequences of L1 dysregulations 
remain largely unknown. Especially in the case of neurodegenerative disorders, it must 
be considered that disease-associated alterations might promote L1 retrotransposition, 
but at the same time, normal aging and stress can influence transposon mobilization. In 
mice, the suppression of L1s mediated by SIRT6, has been shown to be lost during 
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aging and in DNA damage response, leading to a consequent activation of L1 elements 
(Van Meter et al., 2014). Additionally, in Drosophila, it has been extensively described 
that the activation of LINE-like retrotransposons can occur during aging in the brain  (Li 
et al.,2013) and in concomitance with stress response (Specchia et al., 2010).  
A complete study of L1 retrotransposition in different neurodegenerative contexts 
might significantly help in understanding the common and distinctive features of L1 
alterations in brain diseases, in turn providing hints of L1 retrotransposition functions in 
brain physiology.  
The aim of the present study was to contribute to the understanding of L1 
retrotransposition events in Huntington’s disease. 
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6. HUNTINGTON’S DISEASE (HD) 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder 
first described in 1872 by George Huntington in his paper “On Chorea”, thereafter 
termed Huntington’s disease. In 1983 the scientists of the Huntington’s Disease 
Collaborative Research Group found out that the genomic sequence linked to the 
disease was mapping on chromosome 4 (Gusella et al., 1983) and ten years later the 
gene was identified (“The Huntington's Disease Collaborative Research Group.,” 1993). 
The disease-causing mutation was shown to be a polymorphic trinucleotide (CAG) 
repeat in the 5’ region of the IT15 gene that can expand beyond physiological 
thresholds.  
Since then, many aspects of the molecular basis of the pathology have been 
elucidated; however, no cure is currently available for this devastating disease. HD 
affects 4 to 10 cases per 100,000 in Western Europe populations.  
6.1 Clinical manifestations of HD 
Clinical diagnosis of HD is made in the presence of movement disorders typical 
of HD in the context of a family history and genetic test positivity to HD mutation 
(Williams et al., 2007). In addition to movement disorders, typically consisting of 
choreic movements and loss of coordination, HD patients show many other clinical 
manifestations. Psychiatric symptoms are common in HD and they can arise about a 
decade before the onset of motor disturbances. They include mood and personality 
changes, apathy and depression, alterations in memory, learning and planning 
abnormalities and sleep disturbances (Rosenblatt, 2007). As the disease progresses, 
patients develop overt choreiform movements of the whole body, that worsens with 
time, together with facial grimacing and twisting of the trunk and limbs (Bachoud-Lévi 
et al., 2001). Weight loss also appears and could be due to dysphagia or degeneration of 
hypothalamic orexin neurons (Aziz et al., 2008).  
In HD, symptoms typically appear in mid-life, on average around 40 years old, 
but can span between 2 years old, in juvenile HD cases, up to 80-90 years old. The age 
at onset inversely correlates with the extent of the CAG expansion in the HD gene as 
will be explained later. The most common causes of death in HD patients are 
cardiovascular and pneumonic problems deriving from incessant choreic movements, 
Introduction 
 
36 
 
injuries related to falls, poor nutrition and infection. Choking, caused by aspiration of 
food, and suicide are also relatively common causes of death (Di Maio et al., 1993). 
6.2 Neuropathology of the disease 
HD is characterized by a general shrinkage of the brain and degeneration of the 
striatum (caudate and putamen), with specific and gradual loss of efferent medium spiny 
neurons (MSNs) (Reiner et al., 1988). Although the striatum appears to be the most 
affected region of the brain, a specific thinning of cortical ribbon was also found in HD 
patients (Rosas et al., 2002). The loss of cortical mass is an early event in HD pathology 
that worsens with disease progression and mostly occurs at the expenses of the striatum-
projecting neurons in cortical layer V and VI (Hedreen et al., 1991). Atrophy and 
neuronal loss in the hypothalamus have also been reported in HD brains (Kremer et al., 
1991; Petersén and Björkqvist, 2006).  
Studies performed on post-mortem brains revealed the presence of a significant 
microglia activation in the brain regions affected by neurodegeneration, particularly 
striatum, frontal cortex and globus pallidus (Sapp et al., 2001). Other non-neurological 
signs have been also described in HD, including diabetes, peripheral muscle weakness, 
stress-induced apoptotic cell death in lymphocytes and endocrine changes (Ross et al., 
2014).   
6.3 Genetics of HD 
HD is caused by mutations in exon 1 of the IT15 (HTT) gene that encodes for 
huntingtin, a ubiquitously expressed protein (Huntington’s Disease collaborative 
research group 1993). HTT gene is located in chromosome 4p16.3, it contains 67 exons 
and spans over more than 200kb. The 5’end of the gene contains a highly polymorphic 
stretch of CAG trinucleotides that, in wild-type conditions, ranges from 6 to 35 repeats, 
whereas in HD mutant alleles is expanded from 36 to more than 250 CAG repeats 
(Gusella and MacDonald, 2002).  
There is a strong inverse correlation between the number of CAG repeats and the 
age at onset of symptoms: larger CAG expansion relates to earlier ages at onset 
(Andrew et al., 1993). HD alleles carrying CAG repeats between 35 and 40 might show 
late disease onset or might not be penetrant, whereas individuals with more than 60 
CAG typically develop juvenile forms of HD. However the CAG repeat number only 
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partially explains (~70% of cases) the variability in age at onset of the disease, that 
seems to be affected also by other genetic and environmental factors (Neto et al., 2016; 
Rosenblatt et al., 2001). Concerning the genetic background, it has been reported that 
CAG repeats are highly unstable during germline transmission with a tendency to 
increase in size particularly when coming from male germline (Trottier et al., 1994). As 
a result, the age at onset of HD symptoms tends to decrease in successive generations. 
Of note, in addition to the one reported in the germline, somatic tissues of HD 
patients present CAG instability. In HD individuals, higher number of CAG repeats 
have been detected in disease-affected regions as compared to other non-affected 
tissues, including cerebellum, blood, lung, kidney, muscle, spleen, stomach, prostate 
and colon (De Rooij et al., 1995; Telenius et al., 1994). Somatic instability was found to 
be a significant predictor of onset age, with larger somatic expansions in HD-target 
brain regions (primarily striatum and cortex) associated with earlier disease onset 
(Swami et al., 2009, Lee et al.,2012). Similarly to humans, HD mouse models show 
somatic CAG expansion in pathologically affected brain regions and also in kidney and 
liver, whereas it is always lacking in the cerebellum (Mangiarini et al., 1997). This 
phenomenon advances in an age-dependent but not sex-dependent manner (Ishiguro et 
al., 2001; Wheeler et al., 1999). Moreover, CAG repeat size is larger in neurons of the 
striatum and triplets are particularly unstable in terminally differentiated neurons 
(Gonitel et al., 2008). 
Notably, in mouse striatum, repeat instability is differentially modulated by the 
genetic background of mice (Lloret et al., 2006). In humans, HD monozygotic twins 
have been reported to show different clinical symptoms (Georgiou et al., 1999). This 
suggests that other cellular or epigenetic factors or tissue-specific variation in CAG 
repeats might influence the disease. In this context, it has been shown that an important 
contribution to somatic CAG instability derives from DNA handling and mismatch 
repair protein members, including Msh2 (Manley et al., 1999; Wheeler et al., 2003), 
Msh3 (Tomé et al., 2013), Mlh1 and Mlh3 (Pinto et al., 2013). Accordingly, a huge 
genome wide association study on HD affected families with different age at onset 
revealed that increased levels of CAG expansion (both germinal and somatic) associates 
with polymorphic variants of DNA repair genes (Genetic Modifiers of Huntington’s 
Disease (GeM-HD) Consortium, 2015).  
Altogether, these findings show that the brain seems to be particularly susceptible 
to somatic CAG instability in HD, with consequences on the age at onset and 
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progression of the disease. This phenomenon might be modulated by many genetic and 
environmental factors, most of which are still unknown. 
6.4 Huntingtin protein 
Human huntingtin (Htt) is a ~ 350kDa protein containing a polyglutamine (polyQ) 
sequence, encoded by the CAG stretch at the N-terminus. Across the entire protein 
multiple HEAT motif important for protein-protein interactions have been identified 
(Takano and Gusella, 2002). Htt localizes mainly in the cytoplasm, where it frequently 
associates with vesicle membranes, but it can also be found in the nucleus. The N-
terminal portion contains the nuclear localization signal (NLS) and interacts with 
nuclear pore proteins, whereas the C-terminus includes the nuclear export sequence.  
Htt is ubiquitously expressed in humans and rodents, with highest levels in the 
neurons of the central nervous system (DiFiglia et al., 1995). Htt is particularly enriched 
in striatal medium spiny neurons (MSNs) and corticostriatal neurons (Fusco et al., 
1999). Since its discovery as the protein responsible for HD, many efforts have been 
made to understand Htt functions and many roles have been described so far. Here I 
present a brief summary of the most studied ones. 
Physiological functions 
Since Htt knockout mice die around day 8.5, right before the formation of the 
nervous system, it seems that Htt expression is required for the normal early embryonic 
development (Nasir et al., 1995; Zeitlin et al., 1995). Interestingly, Htt is crucial in 
neurogenesis: reduced levels of Htt in embryo stem cells severely compromise the 
specification, self-renewal and proliferation potential of primitive neuronal stem cells 
during the process of neural induction (Nguyen et al., 2013) and, in mice, decreased 
amounts of Htt lead to aberrant brain development and perinatal lethality (White et al., 
1997).  
Wild-type Htt can also act as a protein scaffold: Htt can interact with β-tubulin 
and dynein/dynactin complex and binds to microtubules, therefore participating in 
intracellular trafficking processes (Caviston et al., 2007; Hoffner et al., 2002). Htt has 
been also shown to localize to spindle pole during mitosis, controlling orientation in 
mouse neuronal cells (Godin et al., 2010).  
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Furthermore, Htt seems to exert a transcriptional regulatory function, as 
extensively described for BDNF. In this case, Htt sequesters and inhibits in the 
cytoplasm the REST/NRSF factor, a repressor of BDNF transcription, therefore 
stimulating BDNF expression (Zuccato et al., 2003). It has been also shown that nuclear 
Htt interacts with MeCP2 in mouse and cellular models of HD and that this interaction 
modulates the expression of MeCP2-target genes like BDNF (McFarland et al., 2014). 
Moreover Htt can enhance the activity of the polycomb repressive complex 2 (PRC2), 
an epigenetic silencer that promotes chromatin remodeling, thus regulating the 
expression of several genes involved in stem cell differentiation and embryonal 
development (Seong et al., 2010). 
Involvement of Htt in synaptic connectivity has also been proposed. Htt associates 
with synaptic vesicles and seems to be required for the correct formation of cortical and 
striatal excitatory synapses, as shown by huntingtin silencing in developing mouse 
cortex that leads to an excessive excitatory synapses formation in cortex and striatum, 
followed by gliosis (McKinstry et al., 2014).  
Notably, wild-type Htt protein seems to have antiapoptotic properties as shown 
both in striatal cells and in vivo, where the overexpression of Htt is neuroprotective to 
various apoptotic stimuli (Cattaneo et al., 2001; Leavitt et al., 2006, 2001; Rigamonti et 
al., 2000).   
6.5 Mutant Huntingtin  
CAG expansion leads to the lengthening of the poly-glutamine (polyQ) tract at the 
N-terminus of huntingtin protein. The polyQ expansion in mutant huntingtin (mHtt) is 
likely to confer novel toxic gain of function properties to the protein. However, since 
deletion or inactivation of the wild-type protein also leads to neurodegeneration, the 
hypothesis of a toxicity mediated by the loss of normal Htt functions cannot be 
excluded (Dragatsis et al., 2000; O’Kusky et al., 1999).  
Like other polyQ-expanded disorders, protein aggregates are found in both HD 
post mortem brains and HD mouse models, thus representing a pathological hallmark of 
the disease. Aggregates are composed of misfolded mHtt together with many other 
proteins including ubiquitin (Becher et al., 1998; DiFiglia et al., 1997), proteasome 
subunits and chaperones (Cummings et al., 1998; Warrick et al., 1999), transcription 
factors (Huang et al., 1998; Steffan et al., 2000) or even wild-type huntingtin (Busch et 
al., 2003).  
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The identification of N-terminal Htt fragments in neuronal intranuclear inclusion 
(NIIs) in HD brains suggested proteolytic cleavage of Htt as a toxic mechanism in HD 
(DiFiglia et al., 1997). These fragments can derive from the proteolysis by caspases, 
calpains and other proteases (Gafni et al., 2004; Graham et al., 2006; Hermel et al., 
2004; Kim et al., 2003, 2001; Wellington et al., 1998). Although both wild-type and 
mutant Htt can be cleaved, it seems that mHtt fragments is associated with increased 
toxicity and this might be due to their higher propensity to form nuclear aggregates, 
instead of cytoplasmic aggregates that are less toxic (Hackam et al., 1998; Kim et al., 
1999; Lunkes et al., 2002). The relevance of aggregate toxicity in HD remains 
controversial. The positive correlation between the number of polyQ and the rate of 
aggregation and earlier disease onset suggests a toxic role (Martindale et al., 1998), 
however the inverse correlation between the presence of aggregates and cell death 
suggests a potential protective role of these inclusions, that might sequester toxic 
soluble species (Arrasate et al., 2004) 
6.6 HD pathogenesis 
HD pathogenesis can be viewed as a progressive disease cascade of molecular 
alterations, where the trigger event takes place far before the onset of neurological 
dysfunctions and affects specific neuronal populations (MacDonald et al., 2003). HD 
alterations are primarily detected in striatal neurons, suggesting that HD toxicity starts 
in this brain area. However, in HD brains, loss of cortical mass has been reported in in 
early stages of the pathology (Rosas et al., 2002) and alterations in corticostriatal 
synaptic connectivity in the presence of mHtt seem to occur early in HD mouse models, 
thus preceding striatal toxicity (McKinstry et al., 2014). Accordingly, the BDNF deficit 
in striatal neurons derives from defects in axonal transport of BDNF from the cortex to 
the striatum through the corticostriatal pathway (Gauthier et al., 2004). 
As summarized in figure 11, pathophysiological mechanisms in HD include, in 
addition to aggregate formation, several other processes as diverse as transcriptional 
dysregulation underlying epigenetic alterations, deregulated protein homeostasis leading 
to apoptosis, mitochondrial dysfunction, altered synaptic plasticity, axonal transport 
defects and neuroglia activation. These mechanisms can act both in a synergistic and in 
a sequential way in HD pathogenesis.  
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Figure 11. Mechanisms of neuropathogenesis in Huntington’s disease. Summary of the main 
pathogenic mechanisms in HD. BDNF, Brain derived neurotrophic factor. ROS, reactive oxygen species. 
NMDAR, N-methyl-D-aspartate receptor (Jimenez-Sanchez et al., 2016).  
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Neurogenesis and neuronal maturation impairments in HD 
As previously explained, huntingtin protein plays a crucial role in neurogenesis. 
Consequently, the presence of the mutant protein can lead to neurogenesis 
abnormalities. In fact, impairments in the neurogenic niches of the adult brain have been 
described in HD mouse models: two independent studies showed a decrease in cell 
proliferation rates of NeuN-positive neurons in the hippocampus of HD adult mice (Gil 
et al., 2005; Lazic et al., 2004). However, dysfunctions on both neurogenesis and 
neuronal specification in the presence of mHtt have been also reported brain regions 
which are not strictly neurogenic but severely affected by HD. As shown by Molero and 
colleagues, HD knock-in mice exhibit delayed acquisition of cytoarchitecture and 
altered expression of markers of MSNs neurogenesis in the striatum. Additionally, HD 
striatal progenitors show an abnormal profile of neurogenesis with an increase in the 
pool of intermediate progenitors; an altered cell cycle progression with delayed cell-
cycle exit between E11.5 and E15.5 and an enlarged fraction of cells in an abnormal cell 
cycle state, together with an overexpression of the core pluripotency factor Sox2. 
Furthermore, in HD conditions neural stem cells display impaired lineage restriction, 
reduced proliferative potential and deregulated MSN subtype specification (Molero et 
al., 2009). 
Interestingly, it has been shown that Htt in embryos is able to interact with 
subunits of the epigenetic silencer polycomb repressive complex 2 (PRC2), enhancing 
its activity in a polyQ dependent manner (Seong et al., 2010). In turn, PRC2 is crucial 
for the suppression of transcriptional programs that otherwise would be detrimental for 
neuronal function and survival. As recently reported, PRC2-deficient striatal neurons 
loose de-repression of target genes involved in transcription regulation, neuron 
specification and cell death, with a consequent progressive neurodegeneration (von 
Schimmelmann et al., 2016).  
Altogether, these data show that in HD conditions neuronal specification and 
maturation programs are perturbed and affect particularly striatal neurons, thus 
rendering MSNs more vulnerable to later stressors.  
Remarkably, all these events take place very early in HD brains, suggesting that 
the first pathological alterations triggered by mutant huntingtin arise already during 
embryonal neurogenesis. 
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Transcriptional dysregulation  
Transcriptional dysregulation has emerged as a major and early pathogenic event 
in HD. Microarray studies revealed that expression profiles of both coding and non-
coding RNAs are altered in HD (Luthi-Carter et al., 2002; Sipione et al., 2002). Gene 
expression anomalies have been reported in HD patients (Hodges et al., 2006), are 
recapitulated in HD mouse models (Kuhn et al., 2007).  In many cases, these alterations 
affect mainly striatal neurons, explaining part of the enhanced toxicity of mHtt in this 
tissue. A variety of mechanisms has been proposed to explain how mHtt dysregulates 
transcription patterns, including inhibition of positive regulators or loss of inhibition of 
transcription’s negative regulators. Htt can bind to many transcription regulators both in 
its insoluble and soluble state. Many transcription factors have been reported to 
accumulate in the aggregates and this could suggest that their sequestration might limit 
the ability to bind and regulate their target promoters. On the other hand, many 
transcription factors are able to interact with the N-term of Htt in its soluble state. These 
bindings are altered in case of expanded polyQ and lead to a dysregulation of 
transcription factor activity in a polyQ-dependent fashion (Seredenina and Luthi-Carter, 
2012).  
An additional line of evidence proposes that mHtt affects the levels of active 
transcription factors by influencing their degradation by the proteasome (Cong et al., 
2005). Moreover, Htt can shuttle from the nucleus to the cytoplasm and since the 
nuclear localization signal resides in the N-terminus of the protein, the expanded polyQ 
tract can disrupt the balance of Htt distribution inside cell compartments and promote 
mHtt accumulation in the nucleus (Benn et al., 2005; Wheeler et al., 2002). This is 
particularly relevant if we consider that Htt, in both wild-type and mutant forms, can 
directly bind promoters and several other intronic and intergenic regions, likely leading 
to chromatin remodeling and eventually affecting transcription (Benn et al., 2008).  
One of the most studied evidence of transcriptional alterations in HD is the one 
related to BDNF, a pro-survival factor produced in cortex and fundamental for striatal 
neuron survival. Decreased transcription of BDNF occurs in the in the presence of the 
mutated protein and this leads to degeneration specifically of striatal neurons (Zuccato 
et al., 2001).  
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Epigenetic alterations and noncoding RNAs deregulation 
Gene expression alterations in HD revealed that the epigenetic landscape and the 
non-coding RNA transcriptome can be severely affected in HD.  
Significant changes in DNA methylation have been detected in striatal cells 
expressing mHtt. DNA methylation in promoter regions, that can result either in gene 
activation or silencing, was changed in many genes altered in HD. Importantly, Sox2 
binding sites are targets of altered methylation and, in case of increased methylation, 
loss of Sox2 binding occurs on neurogenesis genes (Ng et al., 2013). However, how 
mHtt triggers DNA methylation, remains largely unknown. Interestingly, it has been 
reported that the presence of polyQ-expanded tract on Htt reinforces its binding capacity 
to MeCP2, and these interactions are stronger in the nucleus compared to the cytoplasm. 
Furthermore in the presence of mHtt, there is an increased binding of MeCP2 to target 
genes, like BDNF, and this leads to the suppression of target gene transcription 
(McFarland et al., 2014). 
In HD, extensive deregulation of histone modifications has also been reported. A 
first hint of this phenomenon came from the study of CBP, a transcriptional co-activator 
with histone acetyltransferase (HAC) activity. The binding of mHtt to the HAC domain 
disrupts its function. Likewise, histone deacetylase (HDAC) inhibitors prevent 
neurodegeneration in cells, Drosophila and mouse models of HD (Ferrante et al., 2003; 
McCampbell et al., 2001; Steffan et al., 2001).  
As for histone acetylation, altered histone methylation levels were detected in HD. 
Differential distribution of H3K9me3 on gene promoters with consequent altered gene 
expression was observed in HD striatal cell lines (Lee et al., 2013). In HD patients and 
transgenic HD mice increased levels of ESET, a H3K9 methyltransferase, were found 
affecting cellular H3K9 trimethylation (Ryu et al., 2006). Moreover, distinctive 
signatures of H3K4me3 have been reported on dysregulated promoters in HD brains 
and in cortex and striatum of 12 months old HD mice. Furthermore, increased levels of 
H3K27me3 are present in HD embryos, embryo stem cells and neural precursors (Seong 
et al., 2010). The role of mHtt on the deposition of these histone marks remains largely 
unclear (Dong et al., 2015; Vashishtha et al., 2013). The modulation of H3K27me3 and 
H3K4me3 has been proposed to strongly depend on PRC2 activity that, in turn, can be 
promoted by Htt (Seong et al., 2010). Interestingly, in embryo stem cells and neural 
precursor cells, normal Htt affects both H3K27me3 levels and distribution, acting on 
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“bivalent loci”. In contrast, mHtt is mainly accompanied by altered H3K4me3 at active 
loci (Biagioli et al., 2015). 
Distinctive chromatin signatures are therefore established in HD conditions 
through mechanisms still largely unknown. This highlights a role of epigenetic 
modifiers, in addition to genetic modifiers, on pathological mechanisms and 
progression. 
In addition to these effects, HD-associated abnormalities in miRNA biogenesis 
have also been described. Altered miRNA expression were registered in HD mice at 
symptomatic stages and in HD patients (Johnson et al., 2008; Packer et al., 2008). 
Notably, in some cases altered expression of miRNAs is accompanied by altered 
expression of key miRNA processing enzymes, as well (Lee and Kim, 2011). Moreover 
polyQ-induced toxicity seems to be modulated by some miRNAs while in a Drosophila 
model of SCA3 (a polyQ disorder), it seems to require an intact miRNA machinery 
processing (Bilen et al., 2006). All this associates with the detection of huntingtin in 
RNA structures such as P-bodies (Savas et al., 2008), stress granules (Ratovitski et al., 
2012) and dendritic RNA granules (Savas et al., 2010). 
DNA damage in HD  
An important contribution to neurodegeneration in HD is provided by apoptosis 
driven by mHtt-induced DNA damage. Its first evidence came from mHtt-expressing 
PC12 cells and human HD fibroblasts where the production of ROS (reactive oxygen 
species) correlates with the activation of a DNA damage response (Giuliano et al., 
2003). Importantly, in cells and mice, mHtt expression associates with accumulation of 
DNA lesions, both single-strand and double-strand breaks. Consequently, the activation 
of DNA damage response leads to phosphorylation of H2AX at the damaged sites and 
stabilization of p53, which in turn promote cytotoxicity (Illuzzi et al., 2009). This 
phenotype is an early event in pathology progression, by far preceding protein aggregate 
formation, and can be modulated by other factors such as Pin1 (Agostoni et al., 2016; 
Illuzzi et al., 2009; Wheeler et al., 2002). Conversely, DNA damage can influence 
huntingtin toxicity in neurons, by altering the state of protein phosphorylation, a process 
long being shown to be crucial for neuronal cell death (Anne et al., 2007).  
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6.7 Hdh Q7/Q111 mouse model 
A large contribution to the elucidation of the various mechanisms involved in HD 
derived from studies performed using mouse models of the disease. Knock-in mice 
carrying the murine Htt protein with expanded polyQ are close models to the HD 
genetic state, since they express mHtt at endogenous levels. Several models of HD 
knock-in mice have been generated (Pouladi et al., 2013), including the Hdh 
Q7/Q111
 
knock-in mouse model that I used in this study.  
The Hdh 
Q7/Q111
 knock-in mouse model has been generated by the insertion of 109 
CAG repeats in the murine homolog HD gene (Hdh) (White et al., 1997). While mouse 
lifespan is not compromised, the first signs of neurodegeneration involve early 
molecular changes that are predictive of later neuropathological phenotypes. These 
alterations hit the striatum as well as the cortex and then, at later stages, also progress to 
other brain regions (MacDonald et al., 2003). For this reason, it represents an ideal 
model to investigate pre-symptomatic HD pathways.  
Importantly, these mice display germline CAG instability together with signs of 
somatic instability particularly in striatum and liver (Wheeler et al., 1999). 
As depicted in figure 12, a progressive disease cascade of pathological events is 
recapitulated in this mouse model. In the first months of life, mice display several 
molecular striatum-specific alterations: progressive accumulation of mHtt in the nucleus 
of striatal neurons starts around 2.5 months (mo) and first neuronal intranuclear 
inclusions are detected at 6 mo of age. ER stress (Carnemolla et al., 2009); somatic 
CAG repeat expansion (Lloret et al., 2006), reduction of cAMP and decreased levels of 
BDNF and its TrkB receptor (Gines et al., 2003; Ginés et al., 2006) are observed from 
the age of 3 mo. As soon as 10 weeks of age, Hdh 
Q7/Q111
 mice manifest behavioral 
abnormalities, including hypoactivity, decreased anxiety, motor learning, long term 
recognition, spatial memory and coordination deficits and impaired olfactory 
discrimination (Giralt et al., 2012; Hölter et al., 2013). Importantly, epigenetic 
alterations triggered by mHtt are recapitulated in these mice: impaired CBP histone 
acetylase activity and increased levels of H3K27me3 in embryoid bodies have been 
reported (Giralt et al., 2012, Molero et al., 2009). Signs of neurodegeneration, reactive 
gliosis and neuronal loss are displayed at older age, from 18mo (Grison et al., 2011; 
Wheeler et al., 2002).  
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Figure 12. Temporal disease cascade in Hdh
Q7/Q111 
mice. A. Huntingtin facilitates PRC2 histone 
H3K27 methyltransferase complex (Seong et al., 2010). B. Nuclear accumulation of mutant Htt in MSNs 
(Wheeler et al., 2002); ER stress (Carnemolla et a.,2009); somatic CAG expansion (Lloret et al.,2006); 
reduction of cAMP and decreased BDNF production and transport from cortex to striatum (Gines et al., 
2003, Zuccato et al,2001). C. Mutant Htt intranuclear inclusions in MSNs. D. Methylation pattern 
alterations and transcriptional dysregulation in cortex and striatum (Ng et al., 2013. McFarland et al., 
2014. Seong et al., 2010); N-terminal inclusions and DNA damage in MSNs (Wheeler et al.,2002). E. 
Neurodegeneration, reactive gliosis and neuronal loss (Grison et al., 2011; Wheeler et al., 2002). Black 
arrow indicate onset of early behavioral abnormalities. E17, embryonal day 17. 
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AIM 
TEs are mobile genetic elements that constitute a large fraction of eukaryotic 
genomes. TEs co-evolved with their host genomes providing tools for genome plasticity 
and regulation. Mounting evidence shows that autonomous L1 transposable elements 
are active in somatic cells of the mammalian brain and that dysregulated activation of 
L1s is associated with neuropathology, such as schizophrenia, Rett syndrome and 
Ataxia telengectasia.  
Likewise, in HD, a series of pathogenic phenotypes that potentially might affect 
L1 retrotransposition has been reported. These alterations include somatic DNA 
instability in disease-affected tissues, transcriptional and DNA methylation 
dysregulations, neurogenesis and DNA repair impairments. 
On the other hand, several genetic and epigenetic modifiers able to modulate HD 
onset and progression have still to be identified, thus suggesting that L1 
retrotransposition might play a role in this scenario. 
The aim of the present study was to investigate whether L1 retrotransposition 
could be altered in HD-affected brains. 
In this work, taking advantage of a novel Taqman qPCR-based approach, we 
provided a complete characterization of L1 retrotransposition events, either at genomic 
and transcriptional levels, in a genetically precise HD mouse model, following the 
entire pathology progression. Subsequently, we described L1-ORF2p expression 
patterns in adult mouse brains, specifically in striatal and cortical brain regions. Finally, 
we interrogated potential regulatory pathways affecting L1 retrotransposition that could 
be altered in mutant huntingtin expressing brains. 
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MATERIALS AND METHODS 
Mouse tissue dissection 
In this study, heterozygous (Hdh
Q7/Q111
) knock-in mice in C57BL/6 background 
were used (Lloret et al., 2006). Animals were provided by prof. M. MacDonald 
(Massachusetts General Hospital, Boston, MA, USA). Animal care, handling and 
subsequent procedures were performed in accordance with the European Community 
Council Directive of November 24, 1986 (86/609EEC) and following SISSA Ethical 
Committee permissions.  
Mice were sacrificed by cervical dislocation. Brains were dissected out and 
immediately transferred to a Petri dish on ice, dropping some PBS on the tissue chop.  
In mice embryos, tissue dissection of the entire cerebral cortex was performed 
after removal of meninges. From E12, striatal tissue samples were collected from the 
region of basal ganglia underlying hippocampus.  
In adult mice, bulk cortex tissue samples were taken from either left and right 
hemispheres, including all cortical regions. Striatum tissue samples were dissected from 
both hemispheres and pulled together for subsequent extractions. 
After dissection, all tissue samples were immediately frozen in liquid nitrogen and 
then stored at -80°C. 
Genomic DNA extraction and quantification 
Phenol/Chloroform DNA extraction 
Dissected tissues (almost 50 mg) were homogenized at room temperature in 2mL 
of lysis buffer (Tris 100mM; EDTA 5mM; SDS 0,5%; NaCl 150mM) using a glass-
Teflon potter. Homogenates were then treated with RNAseA (40µg/mL) (Sigma) at 
37°C for 60 minutes in order to remove any residual RNA. After that, proteinase K 
(Roche) was added at a final concentration of 10µg/mL and samples were incubated at 
37°C, overnight (O/N). 
The day after, genomic DNA extraction was performed using a standard 
phenol/chloroform/isoamyl alcohol method: one volume of phenol (water-saturated, pH 
8-Sigma) was added to each sample, followed by a centrifugation at 10000rpm for 20 
minutes. The aqueous upper phase was collected and then added with 1 volume of 
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phenol : chloroform-isoamyl alcohol (25: 24:1), followed by a centrifugation at 
10000rpm for 10 minutes. Again, the aqueous upper phase was collected in a new tube 
and added with 1 volume of chloroform : isoamyl alcohol (24:1), followed by a 
centrifugation at 10000rpm for 10 minutes. From the resulting aqueous phase DNA was 
finally precipitated by adding two volumes of 100% ethanol so that a visible white flake 
formed. Flakes were then transferred into fresh tubes, containing 70% ethanol and 
centrifuged at 12000 rpm for 15 minutes at 4°C in order to wash and gradually hydrate 
DNA. The DNA pellets were dried from ethanol and then dissolved in 300 µL of Tris 
10mM O/N at RT. Genomic DNA quality was then checked by gel electrophoresis 
using a 0.9% EtBr agarose gel. 
Genomic DNA quantification using Quant-iT™ PicoGreen® dsDNA kit (Invitrogen) 
In order to detect very small differences within very abundant genomic repetitive 
sequences, precisely quantified small amount of genomic DNA has to be used for L1 
copy number variation analysis. According to the literature (Coufal et al., 2009), the 
optimal amount of genomic DNA for this type of analysis is 80 picograms 
corresponding approximately to 12 genomes. To obtain such an accurate DNA 
quantification, we took advantage of Quant-iT™ PicoGreen® dsDNA kit (Invitrogen), 
an ultrasensitive double strand DNA (dsDNA) quantification method able to quantify 
DNA amounts ranging from 25 pg/mL up to 1000 ng/mL.  
First of all, DNA concentrations of each sample were measured by standard 
spectrophotometric techniques, using Nanodrop 2000 (ThermoFisher). According to the 
initial concentration, DNA samples were diluted in TE buffer (10mM Tris-HCl, 1 mM 
EDTA, pH 7,5) to a final concentration of 80 pg/µL. A bacteriophage λ dsDNA 
(provided by the kit) was used to prepare a five-points standard curve, at the following 
concentrations: 0,1 ng/mL, 0,5 ng/mL, 1 ng/mL, 5 ng/mL, 10 ng/mL. Each point of the 
standard curve, the DNA samples and the blank were diluted in TE buffer to a final 
volume of 100 µL, loaded in duplicate in a microtiter plate and added with 100µL of 
working solution (Quant-iT™ PicoGreen® dsDNA reagent diluted 200-fold in TE 
buffer). The plate was gently mixed and incubated for 5 minutes at room temperature, 
protected from light. After incubation, samples’ fluorescence was measured at standard 
fluorescein wavelengths using an EnSpire spectrofluorometer (Perkin Elmer).  Sample 
concentrations were calculated in respect to the standard curve: by plotting fluorescence 
versus DNA concentration of λ DNA, a standard curve was generated and its equation 
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was used to assess the DNA concentration of each sample. DNA concentrations ranging 
from 60 to 100 pg/µL were accepted. 
Total RNA extraction and RT PCR 
Total RNA was extracted from 30 mg of striatum and cerebral cortex tissue 
samples using Trizol reagent according to manufacturer’s instructions (Ambion). To 
remove any residual DNA, RNA samples were treated with DNAse I (Ambion) using 2 
U every 10 ug of RNA, added with SUPERase RNAse inhibitor (Invitrogen) in a 
reaction volume of 50uL and incubated at 37°C for 30min. After this treatment the 
enzyme was inactivated and RNA was purified using Cleanup RNeasy® Mini kit 
according to manufacturer’s instructions (QIAGEN). The RNA concentration and purity 
were determined by spectrophotometric measurement using Nanodrop 2000 
(ThermoFisher) and by running denaturing formaldehyde agarose gel, assessing the 
ratio between 28S and 18S rRNA subunits, approximately near to 2. After that, reverse 
transcription (RT) was performed using iScript cDNA Synthesis kit according to 
manufacturer’s instructions (Biorad). In reverse transcription reactions, 0.5 µg of total 
RNA were used as template in a final reaction volume of 20 µL. For each sample both 
RT+ and RT- reactions were run by, respectively, adding reverse transcriptase enzyme 
or replacing it with an equivalent volume of RNAse free water. 
Quantitative Real-Time PCR (qPCR)  
Quantitative Real-Time PCR (qPCR) is a method of amplification and detection 
of nucleic acids, which allows determining the quantity of a given template with 
accuracy, specificity and high sensitivity over a dynamic wide range. Unlike 
conventional PCR where the amplification product, or amplicon, is detected by an end-
point method, with qPCR it is possible to detect the amplicon at each step of 
amplification, as the reaction progresses. The detection of the amplicon relies on the use 
of fluorescent molecules, such as DNA-binding dyes (i.e. SYBR Green) or fluorescently 
labeled sequence-specific probes (i.e. Taqman probes), whose fluorescent signal is 
proportional to the amount of DNA amplified at each cycle. 
In this study, we performed Taqman-qPCR in L1 specific assays and SYBR 
Green qPCR in MILI expression experiments. qPCRs were performed using CFX96 
Touch™ Real-Time PCR Detection System (Biorad), in a final volume of 20 µL.  
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Taqman-qPCR experiments were performed in duplex using FAM-labeled 
Taqman probes specific for the gene of interest together with VIC-labeled Taqman 
probe specific for the reference gene. PCR mixes were prepared by adding 10x iQ
TM
 
Multiplex Powermix (Biorad), 80pg of genomic DNA or 3ng of cDNA, 0.3 µM of each 
primer, 0.1 µM of each probe, and RNAse free water up to 20uL. PCR cycling 
conditions used were: 1)95°C for 20sec, 2) 95°C for 10 sec, 3)59°C for 30 sec. Steps 2) 
and 3) were repeated 40 times.  
For SYBR Green qPCR experiments, master mixes were prepared by adding 2x 
SYBR Green (Biorad), 10ng of cDNA, 0.2 µM of each primer, and RNAse free water 
up to 20uL. In expression qPCR experiments, we loaded both RT+ and RT- samples to 
control residual genomic DNA contamination. 
Primer and probes sequences are listed in table 1. 
For each qPCR experiment we constructed a standard curve and calculated the 
primer and probe amplification efficiencies E=10 
(-1/slope)
. The amplification efficiencies 
of the target gene and of the reference gene were accepted between 90-100%.  
Relative quantification was assessed by normalizing Ct values of the target gene 
with those of a reference gene, by using the 2
–ΔΔCt 
 method (Livak and Schmittgen, 
2001). In detail, for each sample, the average Ct values of the triplicate for both target 
and reference genes were first calculated and then the average value of the reference 
gene was subtracted to that of the gene of interest, obtaining the ΔCt value:  
ΔCt = average Ct test probe – average Ct reference probe 
Then for each replica, the samples with the highest value of ΔCt was chosen as 
internal calibrator to normalize ΔCt values between samples within a plate and between 
samples run in different plates. In this way, ΔΔCt was calculated:  
ΔΔCt = ΔCt sample – ΔCt calibrator 
Finally, the second derivative value was calculated as follows: 
2 
–ΔΔCt
 = normalized amount of target 
By doing this normalization, any difference in the amount of input DNA between 
samples was compensated and an accurate relative quantification was performed. 
ORF2-L1 Taqman copy number variation assay 
In our laboratory, a novel Taqman-qPCR based assay was developed in order to 
assess L1 copy number variation in mouse genomic DNA, based on that published by 
Coufal and colleagues in humans (Coufal et al., 2009). Our Taqman qPCR strategy was 
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planned considering that probes complementary to the murine L1-ORF2 sequence are 
able to detect the entire L1 repertoire in the mouse genome, including both full length 
and truncated forms, which correspond to both original and retrotransposed L1 copies 
(Figure 13). The L1-ORF2 probe that we used was labeled with FAM dye at the 5’end 
and with MGB quencher at the 3’end according to provider’s instructions (Applied 
Biosystem). 
In order to perform a relative quantification of the genomic ORF2 content, we 
designed a Taqman probe against the centromeric microsatellite sequence or MICSAT 
(about 1 million copies), to be used as a reference gene with high number of copies in a 
duplex qPCR reaction. MICSAT-probe was labeled with VIC dye at the 5’end and with 
MGB quencher at the 3’end according to provider’s instructions (Applied Biosystem). 
Sequences of primers and probes are listed in table 1. 
 
 
Figure 13. Schematic representation of ORF2-L1 Taqman assay. Blue boxes represent Taqman 
probes specific for L1 ORF2-sequence and able to detect both full length L1 and 5’truncated L1 copies 
present in the genome. 
5’UTR-L1 Taqman expression assay 
In order to detect endogenous L1 expression in mouse tissues, we developed new 
Taqman assays able to target only full length active L1 elements. Since the murine L1-
5’UTR is composed by different repetitive monomers whose organization characterizes 
different L1 subfamilies (Goodier et al., 2001), we designed Taqman probes and primer 
pairs specific for active mouse L1 subtypes, corresponding to A, Tf and Gf L1 5’UTRs. 
In this way, we were able to follow the expression patterns of each L1 subfamily (figure 
14). L1-5’UTR Taqman probes were labeled with FAM dye at the 5’end and with MGB 
quencher at the 3’end, according to provider’s instructions (Applied Biosystem). In 
order to obtain a relative quantification of L1 5’UTR mRNA levels against a reference 
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housekeeping gene, we performed a GeNorm analysis in order to understand which was 
the most stable housekeeping gene among our set of samples, taking into account the 
developmental stage, the tissue and the HD genotype. To this aim we tested by GeNorm 
beta actin, GAPDH, Hmbs, Pgk1, UbC and Ywhaz in a representative number of 
samples of either cortex and striatum, at E14, P0 and 3mo, including both HD and WT 
mice. At the end, Ubc turned out to be the most suitable housekeeping gene for our 
experimental conditions, having a GeNorm M value < 0.5 in all samples analyzed. UbC 
Taqman probe was labeled with VIC dye at the 5’end and with MGB quencher at the 
3’end according to provider’s instructions (Applied Biosystem). Primers and probes 
used are listed in table 1. 
 
 
Figure 14. Schematic representation of 5’UTR L1 Taqman assay on full length L1s. Triangles 
represent 5’UTR monomers present on full length mouse L1 elements. Purple, yellow and green boxes 
indicate, respectively, Gf, A and Tf specific Taqman probes, able to detect only full length L1 mRNAs. 
Statistical analysis 
For each assay, at least three independent qPCR technical replicates were 
performed on all samples.  
In scatter plots, each dot represents the average value for each biological replica 
derived from three qPCR replicates. Horizontal black line indicates the mean value of at 
least six independent biological replicas. Error bars indicate standard deviations.  
Bar plots report mean value of at least six independent biological replicas. Error 
bars represent standard error. 
In Line graphs, each dot represents the mean value of at least six independent 
biological replicas. Error bars represent standard error.  
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Statistical analyses were performed by means of two tailed, Mann Whitney non-
parametric test, and taking advantage of GraphPad Prism 5 Statistics Toolbox. * p 
value<0.05, ** p value<0.01. 
MILI and MIWI2 PCR 
In order to detect MILI and MIWI2 expression in adult cortex and striatum 
samples, we performed end point PCR on the same cDNAs previously used for L1 
qPCR experiments that displayed no genomic contamination. PCRs were performed 
using CFX96 Touch™ Real-Time PCR Detection System (Biorad) machine, in a final 
volume of 50 µL, using ExTaq DNA polymerase (Takara).  
Primers used are listed in table 1. 
 
Table 1. List of primers and probes used for qPCR and PCR experiments 
oligo name 5'-3' sequence
ORF2 FOR CCCTCAACAGAGGAATGGAT
ORF2 REV CCATCCATTTGGCTAGGAAT
ORF2 probe AAATGTGGTACATCTACACAATGGA
MICSAT FOR GAACATATTAGATGAGTGAGTTAC
MICSAT REV GTTCTACAAATCCCGTTTCCAA
MICSAT probe ACTGAAAAACACATTCG
5'UTR Gf FOR CCAAACACCAGATAACTGTACACC
5'UTR Gf REV CGTGGGAGACAAGCTCTCTT
5'UTR Gf probe TGAAAGAGGAGAGCTTGCCT
5'UTR A FOR TGCCCACTGAAACTAAGGAGA
5'UTR A REV GCTTGTTCTTCAGGTGACTCTGT
5'UTR A probe TGCTACCCTCCAGGTCTGCT
5'UTR Tf FOR TGAGCACTGAAACTCAGAGGAG
5'UTR Tf REV GATTGTTCTTCTGGTGATTCTGTTA
5'UTR Tf probe GAATCTGTCTCCCAGGTCTG
UbC FOR ACAGACGTACCTTCCTCACC
UbC REV CCCCATCACACCCAAGAACA
UbC probe AAAAAGAGCCCTCCTTGTGC 
MILI FOR AAGGACAGAGAAGAACCCCG
MILI REV ATACTACTGGCTGCTCGTCC
MIWI2 FOR CCCGACTCGTGGATGACAT
MIWI2 REV GGCTTCACAGACCAGTCAATG  
Materials and Methods 
56 
 
Protein extraction and western blot  
Total protein lysates from cerebral cortex and striatum were obtained using Trizol 
reagent according to manufacturer’s instructions (Ambion) after RNA extraction and 
then sonicated for complete lysis. Protein lysates concentrations were determined by 
Bradford (BIORAD) assay using a calibration curve built with serial dilutions of bovine 
serum albumin (BSA). 80 µg of cortex and striatum lysates and 20 µg of testes lysates 
were mixed with 2X SDS sample buffer. Samples were boiled at 95°C for 5 min and 
separated by SDS-PAGE electrophoresis. Proteins were then transferred to 
nitrocellulose membrane (GE Healthcare) by blotting at 100V for 1 hour. Membranes 
were blocked with 5% non-fat milk in Tris Buffer Saline Tween20 (TBST) and then 
incubated at 4°C overnight with primary antibody diluted in 5% milk-TBST, with 
agitation. The day after, membranes were washed three times in TBST and then 
incubated with secondary HRP-conjugated antibody diluted in 5% milk-TBST at RT for 
1 hour. Proteins bands were developed using ECL developing system (GE Healthcare).  
The following primary antibodies were used: anti MILI (1:1000, MABE363, 
Millipore), anti MIWI2 (1:500, Abcam), anti beta actin (1:20000, Sigma). 
Immunohistochemistry  
Mice were transcardially perfused with 4% paraformaldehyde in PBS (pH 7.4). 
The brain was rapidly removed from the skull, post-fixed in PFA 4% o/n at 4°C and 
then transferred in 30% sucrose/PBS until it sunk. Brain samples were included in 
Killik medium (Bio-Optica) and then flash frozen by immersion in liquid nitrogen. 
Coronal cryosections of 16µM thickness were prepared cutting throughout the striatum 
(+3mm : -3mm from Bregma).  
For immunohistochemistry, slices were first rinsed in Tris Buffered Saline (TBS) 
solution for 10 min at room temperature (RT), then added with 0.1 M glycine/TBS for 
10 min at RT to quench autofluorescence and then quickly rinsed three times in TBS. 
After that, slices were incubated for 1 hour at RT in blocking solution (1% BSA, 10% 
FBS,1% fish gelatin in TBS) and then at RT overnight with primary antibody in TBS 
added with 0.1% fish gelatin, 0.3% Triton X-100, 1% BSA. The next day, sections were 
incubated with secondary antibodies: first with biotinylated antibody for 1h30 min at 
RT, and then with streptavidin Alexa 488 conjugated antibody for 1h30 min at RT. 
After each antibody incubation, slices were washed 3 times in TBS. For nuclei staining, 
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DAPI was added during the streptavidin A488 incubation at a dilution of 1:500. Finally 
slices were rinsed 2 additional times in H2O and slides were mounted using Vectashield 
mounting medium. Images were captured using Leica TCSSP2 Confocal microscope.  
The following primary antibodies were used: anti LINE-1 (M300) (1:100, Santa 
Cruz Biotechnology), anti MILI (1:10, Millipore).  
Chromatin immunoprecipitation 
Striatum tissue samples (~50mg) were first minced into small pieces with minimal 
thawing, then added with 1 mL of ice cold PBS 1X and completely homogenized using 
a glass-Teflon potter. For crosslinking, homogenates were incubated with 1% PFA in a 
final volume of 2mL at RT for 20 minutes, rocking. PFA was quenched by incubation 
with 125mM of glycine at RT for 5 minutes, rocking. Lysates were then collected by 
centrifugation at 5000 rpm, at RT for 5 minutes and then washed two times with 500µL 
of ice-cold PBS 1X to remove any residual PFA and glycine.  
Then, cell lysis was performed in 500uL of cell lysis buffer (10mM HEPES pH 8, 
85mM KCl, 0.5% NP-40) added with 25X proteinase inhibitors. Samples were 
homogenized by douncing, incubated on ice for 10min and finally collected at 5000rpm, 
at RT for 5 minutes. After that, lysates were resuspended in 300 uL of nuclei lysis 
buffer (1% SDS, 10mM EDTA, 50mM Tris-HCl pH8) added with 25X proteinase 
inhibitors and incubated on ice for 10min. Samples were then transferred into sonication 
tubes and sonicated using Bioruptor Sonicator NGS (Diagenode) using the following 
settings: high power, 30 seconds ON and 30 seconds OFF per each cycle, 30 cycles. 
After sonication, 1/30 of sonicated DNA fraction was saved, decrosslinked, DNA was 
extracted, quantified using Nanodrop 2000 (ThermoFisher) in order to have an estimate 
of sonicated chromatin concentration and run on a 1% EtBr agarose gel to assess 
chromatin shearing to be around 200bp.  
In the meanwhile, antibody-magnetic Dynabeads® M-280 Sheep anti-Rabbit IgG 
(Invitrogen) complexes were prepared by first washing beads twice in blocking solution 
(0.5% BSA in 1x PBS) and then by incubating beads with IgG or 5ug of antibody per 
each immunoprecipitation in blocking solution at 4°C, overnight, rocking. The day 
after, beads-antibody complexes were washed again 3 times in blocking solution to 
remove any unbound antibody and resuspended in 100uL of blocking solution, ready to 
be used for immunoprecipitation. 
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The sonicated DNA, after checking the chromatin fragmentation size, was 
centrifuged at 20000g, at 4°C for 30 minutes to pellet cell and nuclear debris and diluted 
1:10 in ChIP Dilution buffer (0.01% SDS, 0.275% Triton X-100, 1mM EDTA, 16.7mM 
Tris-HCl pH 8, 167 mM NaCl) added with 25X proteinase inhibitors. After having 
removed a control aliquot to be used as INPUT sample, sonicated chromatin was split in 
equivalent portions per each immunoprecipitation (IP) (approximately 20ug per IP) and 
incubated with antibody-beads complexes, previously prepared, at 4°C, overnight, 
rocking.  
Chromatin-antibody complexes were then sequentially washed with increasing 
stringency salt buffers as follows: 2 times in low salt buffer (20mM Tris-HCl pH 8, 
150mM NaCl, 0.1% SDS, 1% Triton X-100, 2mM EDTA), 2 times in high salt buffer 
(20mM Tris-HCl pH 8, 500mM NaCl, 0.1% SDS, 1% Triton X-100, 2mM EDTA), 2 
times in LiCl buffer (10mM Tris-HCl pH 8, 250mM LiCl, 1% NP-40, 1% sodium 
deoxycholate, 1mM EDTA). At each wash, samples were incubated for 5 minutes, at 
4°C, rocking and then collected using pre-chilled magnetic stand. Finally samples were 
washed once in TE buffer (10mM Tris-HCl pH 8, 1mM EDTA) and spin at 1000 x g for 
3 min at 4°C. Immunoprecipitated chromatin was then eluted in elution buffer (1% 
SDS, 100mM NaHCO3, 5mM DTT), at 65°C for 15 minutes, shaking. An aliquot of 
eluted IP sample was saved to check immunoprecipitation specificity by Western Blot 
analysis. The remaining eluted IP chromatin was collected and decrosslinked at 65°C 
overnight, together with INPUT chromatin sample. After that, proteinase K (1mg/mL) 
(Roche) treatment was performed at 37°C for 2 hours followed by Phenol/Chloroform 
DNA extraction. IP and INPUT DNA samples were then treated with RNAse A 
(80ug/uL) (Sigma) and purified using MinElute kit (QIAGEN) according to 
manufacturer’s protocol. Finally, DNA concentration was measured using Quant-iT™ 
PicoGreen® dsDNA kit (Invitrogen).  
Four independent biological replicas were performed per each chIP experiment. 
Immunoprecipitation specificity with the expected antibody was assessed by 
Western Blot analysis on IP and IgG samples for each replica. 
ChIP enrichments were assessed by SYBR Green-qPCR using CFX96 Touch™ 
Real-Time PCR Detection System (Biorad), loading 100 pg of ChIP DNA and an equal 
amount of un-enriched INPUT DNA. Enrichments were calculated from 4 independent 
biological replicas. For chIP experiments on histone modifications, a gene desert region 
located on mouse chromosome 6 (Active Motif) was used as internal negative control 
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for normalization of chIP DNA enrichments. DNA enrichments were assessed as 
follows: chIP DNA enrichment for L1 5’UTR = [(2^ (-ΔCt))*100] with ΔCt = [(avg Ct 
IP-Avg Ct input (for L1 5’UTR)) - (avg Ct IP- Avg Ct input (for chr6 gene desert 
region)]. 
For chromatin immunoprecipitation the following antibody were used: anti 
H3K4me3 (Millipore), anti H3K9me3 (Millipore), anti H3K27me3 (Millipore) and anti-
MeCP2 (Abcam) 
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RESULTS 
Preliminary data 
In humans, it is known that several regions of adult brain, in particular neurogenic 
compartments like hippocampus and olfactory epithelium, and frontal cortex display an 
increased number of genomic L1 copies as compared to other somatic non nervous 
tissues, such as heart and liver (Coufal et al., 2009, Baillie et al., 2011).  
We asked ourselves whether this pattern of L1 copy number in different tissues 
might be present also in mice. To this aim, in a previous study performed in our 
laboratory, the rate of L1 retrotransposition in different mouse somatic tissues was 
assessed, with a particular interest on the comparison between brain and non-nervous 
tissues. 
As explained in detail in the methods section, L1 CNV analysis in mouse genome 
was performed with a Taqman qPCR assay developed in our laboratory by adapting the 
procedure described for human samples by Coufal and colleagues. In brief, in order to 
account for the entire repertoire of L1 elements present in the mouse genome (more than 
100000 copies) we used a Taqman probe complementary to the ORF2 sequence of a 
murine L1, able to detect both full length L1 elements and 5’truncated L1 copies that 
underwent retrotransposition. Then, in order to normalize the amount of ORF2p 
sequences on a reference gene, we designed an assay against the high copy number 
invariant microsatellite centromeric sequence, MICSAT (about 500000 copies). With 
this technology, a relative quantification of the total number of genomic L1s could be 
made, thus giving an estimate of the rate of L1 retrotransposition events in a given 
tissue.  
Similarly, to the experiment performed in humans, we analyzed genomic DNA 
extracted from tissue samples of hippocampus, cortex and olfactory epithelium, together 
with two non nervous organs corresponding to liver and kidney. Samples derived from 
5 wild-type C57Black mice at 3 months of age. Three independent qPCR replica were 
performed.  
From this study, consistent with what observed in humans, a marked alteration in 
total L1 copy number was observed in the brain regions compared to non-brain tissues 
(figure 15). In particular, higher amounts of genomic L1 elements were found in adult 
hippocampus, olfactory epithelium and cortex relative to liver and kidney. A paired t-
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test comparing the different brain samples to liver and kidney showed that the increase 
in ORF2 content in the brain was statistically significant. In detail, we observed that 
ORF2 copies in olfactory epithelium and cortex were increased of 14% (p-value = 
0.001) and 12% (p-value = 0.01), respectively, compared to liver and of 22% (p-value = 
0.006) and 19% (p-value = 0.02) compared to kidney. The difference in relative L1-
ORF2 copies in hippocampus was less evident when compared to liver (hippocampus 
contains on average 10% more ORF2 than liver), but it became significant when 
compared to kidney (18% (p-value = 0.04) more L1 copies in hippocampus than 
kidney). 
Overall, since increased L1-ORF2 copies result from active L1 retrotransposition, 
we may conclude that, in adult mouse, somatic endogenous L1 retrotransposition is 
higher in the brain than in non-brain tissues, thus confirming data reported in human 
hippocampus and frontal cortex (Coufal et al., 2009, Baillie et al.,2011). 
 
 
Figure 15. The copy number of genomic L1s is increased in mouse adult brain regions as 
compared to non-nervous tissues. Relative quantification of total number of genomic L1 elements 
obtained by qPCR using the ORF2-MICSAT Taqman assay. L, liver; K, kidney; H, Hippocampus; OE, 
olfactory epithelium; C, cortex. The amount of L1 ORF2 sequences is significantly higher in all brain 
regions respect to liver and kidney. Scattered graphs represent L1 ORF2 relative amount in 5 adult mice. 
Each symbol represents the average of 3 qPCR independent replica. Red lines represent the average of all 
samples. Error bars indicate standard deviations. *P<0.05; **P<0.01; ***P<0.001 resulting from t-student 
paired test.  
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1. Characterization of L1 retrotransposition events in a mouse 
model of HD 
In the last decade, several works, mostly taking advantage of engineered L1 
reporter assays and L1 CNV analysis, showed that L1s are active during neurogenesis 
and that dysregulated activation of L1s is associated with neuropathology, such as 
schizophrenia, Rett syndrome and ataxia telengectasia (ATM) (Bundo et al., 2014; 
Coufal et al., 2011; Muotri et al., 2010).  
In Huntington’s disease (HD), pathogenic mechanisms including somatic CAG 
instability, altered neurogenesis, transcriptional dysregulation, epigenetic alterations and 
DNA damage may potentially alter L1 retrotransposition activity. 
At the same time, several genetic and epigenetic modifiers, able to modulate age 
at onset and progression of the disease, remains largely uncharacterized, suggesting that 
L1 retrotransposition might play a role in this scenario.  
The first step that we made towards an understanding of L1 dynamics in HD was 
the characterization of L1 retrotransposition events in a precise genetic mouse model of 
HD. 
1.1. L1 copy number variation analysis in WT/KI compared to WT/WT mice 
First, we assessed the number of genomic L1 copies in HD mice as compared to 
controls. To this aim, we performed L1 copy number variation (CNV) analysis in cortex 
and striatum, the most affected tissues in HD, of Hdh 
Q7/Q111
 (WT/KI) and Hdh 
Q7/Q7 
(WT/WT) mice. To this purpose, we took advantage of the ORF2-MICSAT Taqman 
assay able to account for the entire repertoire of L1 copies in the mouse genomes, 
including both full length and truncated forms.  
It has been demonstrated that mutant huntingtin can trigger early alterations 
during the embryonic development (Molero et al., 2009, Seong et al., 2010). At the 
same time, somatic retrotransposition of an engineered L1 has been reported during 
early embryonal neurogenesis, in particular between E8.5 and E10.5 (van den Hurk et 
al., 2007, Muotri et al., 2005). For these reasons, we decided to analyze L1 CNV in both 
embryonic and adult stages. In detail, L1 CNV analyses were performed at E12, right 
after the bulk of L1 retrotransposition reported by Muotri et al. and corresponding to the 
beginning of telencephalic neurogenesis; at P0, corresponding to the end of 
telencephalic neurogenesis; at three progressive adult ages when HD-specific 
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phenotypes are manifest in affected neurons: 3 months of age (3mo), when mutant 
huntingtin accumulates in the nucleus of medium spiny neurons and a reduced 
production and transport of BDNF from the cortex to the striatum is observed (Wheeler 
et al., 2002), (Zuccato et al., 2001); 12 months of age (12mo), when medium spiny 
neurons display Htt nuclear inclusions and DNA damage, and cortex and striatum are 
affected by alterations in methylation patterns and transcriptional dysregulation 
(McFarland et al., 2014; Ng et al., 2013; Seong et al., 2010); 24 months of age (24mo) 
when neurodegeneration of medium spiny neurons and reactive gliosis is detected 
(Wheeler et al., 2002). 
For each assay at least three independent technical replicas were performed. For 
each developmental stage and genotype, we analyzed at least 6 independent biological 
replicas. 
Therefore summarizing, by assessing relative ORF2-L1 content, we compared L1 
CNV in the striatum and in the cerebral cortex of WT/WT and WT/KI mice, at the 
stages of E12, P0, 3mo, 12 mo and 24 mo.  
As shown in figure 16, L1 CNV analysis in the striatum revealed no significant 
differences between WT/WT and WT/KI mice in relative ORF2 genomic content. This 
was consistent for all the developmental stages analyzed, both at pre-natal and post-
natal ages (figure 16). As indicated by each dot of the scatter plot, a certain level of 
inter-individual variability was observed at E12 and P0. However, in post-natal stages 
the deviations among biological replicas were very small. 
 
In the cerebral cortex, similarly to the striatum, we observed equivalent levels of 
genomic L1 elements in WT/WT and WT/KI mice, at all developmental stages analyzed 
(figure 17). As for the striatum, also in the cortical tissue samples, high levels of 
variability between mice were detected at E12 and P0. However, in the case of cortex, a 
certain level of inter-individual variability was registered also in post-natal stages, 
particularly at 3mo of age. 
 
Altogether these data show that both in the striatum and in the cortex of E12, P0 
and adult mice, equivalent levels of L1 genomic copies are present in Hdh 
Q111/Q7
 and 
Hdh 
Q7/Q7 
mice.  
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Figure 16. Genomic L1 copy number in striatum of WT/WT and WT/KI mice. Relative 
quantification of total genomic L1 elements using ORF2-MICSAT Taqman assay. E12, embryonal day 
12; P0, date of birth; 3mo, 3 months of age; 12mo,12months of age; 24mo, 24 months of age. Similar 
levels of L1-ORF2 sequence are detected between WT/WT and WT/KI mice. Each dot of the scatter plot 
represents the average of 3 independent qPCR replica. The average value between biological replicas is 
shown with black horizontal line. Error bars indicate standard deviation.  
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Figure 17. Genomic L1 copy number in cortex of WT/WT and WT/KI mice. Relative 
quantification of total genomic L1 elements using ORF2-MICSAT Taqman assay. E12, embryonal day 
12; P0, date of birth; 3mo, 3 months of age; 12mo,12months of age; 24mo, 24 months of age. Similar 
levels of L1-ORF2 sequence are detected between WT/WT and WT/KI mice. Each dot of the scatter plot 
represents the average of at least 3 independent qPCR replica. The average value between biological 
replicas is shown with black horizontal line. Error bars indicate standard deviation. 
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1.2. L1 expression analysis in WT/KI compared to WT/WT mice 
In parallel to L1 CNV analysis, in order to investigate whether L1 transcription 
can be altered by mutant huntingtin, we also performed L1 expression analysis. To this 
purpose, we compared endogenous L1 transcript levels of WT/KI (Hdh
Q7/Q111
) and 
WT/WT (Hdh 
Q7/Q7
) mice, using RNA extracted from striatum and cerebral cortex.  
To carry out endogenous L1 expression analysis we developed a Taqman qPCR-
based approach able to detect only full length active L1 elements, transcribed from the 
endogenous 5’UTR sense promoter. Since the murine genome is scattered with several 
L1 classes that differ for the monomeric organization at their 5’UTR, we designed 
Taqman probes specific for each 5’UTR-L1 subtype. In this way, we were able to 
discriminate between the different subfamilies of active L1s, that are Gf, A and Tf. 
Transcript levels of each L1 5’UTR were normalized with the housekeeping gene 
ubiquitin C (UbC), since it resulted to be the most stable housekeeping gene for our 
experimental conditions, according to the GeNorm analysis that considered the different 
stages, tissues and genotypes.  
As previously mentioned, neurogenesis alterations and early epigenetic changes in 
the presence of mutant huntingtin can be detected in HD mice already during embryonal 
stages (Seong et al., 2010, Molero et al., 2009). Therefore, we performed L1 expression 
analysis starting from embryonal day 10 up to 24 months of age. In detail, we 
considered four embryonal stages: E10, E12, E14 and E17; the date of birth (P0) and the 
same adult stages considered for L1 CNV: 3 months, 12 months and 24 months. 
Similarly to L1 CNV, per each stage, we analyzed both striatum and cortex. At 
E10 striatum and cortex are not yet differentiated and therefore, at this embryonal stage, 
we analyzed only the common precursor, here simply referred as “cortex”. For each 
assay at least three independent technical replicas were performed.  
For each assay at least three independent technical replicas were performed. For 
each developmental stage and genotype, we analyzed at least 6 independent biological 
replicas.  
L1 expression in embryos and at P0 
The expression analysis of full length Gf, A and Tf L1 elements in the striatum of 
E12, E14, E17 and P0 mice revealed similar levels of L1 mRNAs between WT/WT and 
WT/KI mice (figure 18) at all the developmental stages analyzed. 
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Bar plots summarize the results obtained for each L1 subfamily and show that 
expression patterns are similar for L1 5’UTR Gf, L1 5’UTR A and L1 5’UTR Tf 
subfamilies. 
Detailed scatter plots showing distribution of all biological replicas are shown in 
Appendix. 
 
 
Figure 18. Full length L1 mRNA levels are similar in the striatum of WT/WT and WT/KI 
mice in late embryos and at P0. Relative quantification of 5’UTR L1 mRNA levels in the striatum 
during late embryonal development. E12, embryonal day 12; E14, embryonal day 14; E17, embryonal 
day 17; P0, date of birth. 5’UTR Gf, 5’UTR A, 5’UTR Tf refer to full length Gf, A and Tf L1 subfamilies 
present in the mouse genome. Relative 5’UTR L1 mRNA levels are normalized with the housekeeping 
gene UbC. L1-5’UTR transcript levels are equivalent between WT/WT (light blue) and WT/KI (dark red) 
mice. 3 independent qPCR replicas were performed on each biological sample. Each bar represents 
average value of six independent biological replicas (n=6). Error bars indicate standard error. 
In the cerebral cortex (figure 19), similarly to what shown in the striatum, we 
observed comparable levels of full length L1 transcripts between WT/WT and WT/KI 
mice. This was true for all the three L1 subfamilies considered and in all embryonal 
stages as well as at P0.  
Detailed scatter plots showing distribution of all biological replicas are shown in 
Appendix. 
Results 
68 
 
 
Figure 19. Full length L1 mRNA levels are similar in the cortex of WT/WT and WT/KI mice 
in late embryos and at P0. Relative quantification of 5’UTR L1 mRNA levels in the cortex during late 
embryonal development. E10, embryonal day 10; E12, embryonal day 12; E14, embryonal day 14; E17, 
embryonal day 17; P0, date of birth. 5’UTR Gf, 5’UTR A, 5’UTR Tf refer to full length Gf, A and Tf L1 
subfamilies present in the mouse genome. Relative 5’UTR L1 mRNA levels are normalized with the 
housekeeping gene UbC. L1-5’UTR transcript levels are equivalent between WT/WT (light blue) and 
WT/KI (dark red) mice. 3 independent qPCR replicas were performed on each biological sample. Each 
bar represents average value of six independent biological replicas (n=6). Error bars indicate standard 
error. 
L1 expression in adult stages 
To provide a complete characterization of L1 expression throughout the lifespan 
of the HD mice, in addition to embryos, we analyzed the same adult stages considered 
for L1 CNV (3mo, 12mo and 24mo mice) following the progressive manifestation of 
HD phenotypes that specifically occurs at the level of striatum and cortex. 
Results 
69 
 
In the the striatum, at 3mo of age, we have not found significant alterations in 
WT/WT compared to WT/KI mice, for none of the three L1 5’UTR subtypes (figure 
20a). However, at 12mo of age (figure 20b), interestingly, we observed a significant 
reduction (about 20%) of L1 transcript levels in WT/KI mice compared to WT/WT. 
Notably, this decrease was conserved between all the three L1 subfamilies. Later on, at 
24 mo of age, equivalent levels of L1 mRNAs could be detected between WT/KI and 
WT/WT mice (figure 20c). 
Detailed scatter plots showing distribution of all biological replicas are shown in 
Appendix. 
 
 
Figure 20. Full length L1 mRNA levels are decreased in the striatum of 12months old WT/KI 
mice. Relative quantification of 5’UTR L1 mRNA levels in the striatum of adult mice. 3mo, 3 months of 
age; 12mo, 12 months of age; 24mo, 24 months of age. 5’UTR Gf, 5’UTR A, 5’UTR Tf refer to full 
length Gf, A and Tf L1 subfamilies present in the mouse genome. Relative 5’UTR L1 mRNA levels are 
normalized with the housekeeping gene UbC. At 12mo of age, L1-5’UTR expression of all three L1 
subfamilies is significantly decreased in WT/KI (dark red) mice as compared to controls (WT/WT, light 
blue). 3 independent qPCR replicas were performed on each biological sample. Each bar represents the 
average value of twelve independent biological replicas (n=12). Error bars indicate standard error. 
*P<0.05 resulting from Mann Whitney unpaired test. 
As for the striatum, also from the analysis of L1 expression in adult cerebral 
cortices, we could conclude some original observations. On one hand, at 3mo of age, we 
observed higher levels (~ 25% increase) of L1 5’Gf mRNA in WT/KI mice compared to 
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controls. This increase was not shared with the other two L1 subfamilies (A and Tf) 
(figure 21a). On the other hand, no differences between WT/WT and WT/KI mice were 
detected at 12 mo of age for none L1 5’UTR classes (figure 21b). But interestingly, at 
24 mo, similarly to what observed at 3mo, WT/KI mice displayed a strong activation of 
L1 transcription. Notably, the L1 mRNA overexpression in 24mo WT/KI mice was 
consistent in Gf, A and Tf L1 subtypes (figure 21c). Detailed scatter plots showing 
distribution of all biological replicas are shown in Appendix. 
 
 
Figure 21. Full length L1 mRNA levels are increased in the cortex of 3 months and 24 
months old WT/KI mice. Relative quantification of 5’UTR L1 mRNA levels in the cortex of adult mice. 
3mo, 3 months of age; 12mo, 12 months of age; 24mo, 24 months of age. 5’UTR Gf, 5’UTR A, 5’UTR 
Tf refer to full length Gf, A and Tf L1 subfamilies present in the mouse genome. Relative 5’UTR L1 
mRNA levels are normalized with thw housekeeping gene UbC. At 3mo of age, relative L1-5’UTR Gf 
expression is significantly higher in WT/KI (dark red) mice as compared to controls (WT/WT, light blue). 
At 24 mo of age, L1 5’UTR mRNA levels of all three L1 subfamilies are consistently increased in WT/KI 
mice relative to WT/WT mice. 3 independent qPCR replicas were performed on each biological sample. 
Each bar represents average value of twelve independent biological replicas (n=12). Error bars indicate 
standard error. *P<0.05, **P<0.01 resulting from Mann Whitney unpaired test. 
1.3. Endogenous L1 expression profile during brain development 
High levels of L1 mRNAs, leading in some cases to retrotransposition events, 
have been extensively described during the early stages of embryo development 
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(Fadloun et al., 2013; Kano et al., 2009; Vitullo et al., 2012). Moreover, neural 
precursor cells (NPCs) have been demonstrated to be able to support L1 
retrotransposition of an engineered L1 reporter construct (Muotri et al., 2005). However 
little is known about the physiological L1 transcription dynamics during embryonal 
neurogenesis and in the adult differentiated brain.  
Here, in addition to compare L1 transcript levels between WT and HD mice, the 
analysis of L1 expression in four late embryonal stages (E10, E12, E14, E17), at P0 and 
in adult mice (3mo, 12mo, 24mo), allowed us to follow the transcription dynamics of 
full length L1 elements during development. By plotting the average value of relative 
L1 mRNA levels at each developmental stage, we described the expression profiles of 
each L1 subfamily in the developmental window going from embryonal stage E10 until 
24 mo of age, in striatum and cortex. 
L1 expression profiles in striatum 
In the striatum, we evidenced a wave of L1 transcription during late embryonal 
development. As shown in figure 22, in both WT/WT and WT/KI mice, L1 expression 
only slowly increased during the first phases of striatal differentiation between E10 and 
E12, but then this trend significantly increased between E12 and E14 up to E17 when 
L1 transcript levels reached their maximum during embryogenesis. After E17, L1 
transcription decreased until P0 and this slowdown was more marked in WT/KI mice. 
After birth, between P0 and 3mo no significant changes were observed, but from 3 mo 
to 12 mo, surprisingly, a burst of L1 transcription, severely impaired in WT/KI mice, 
was detected in WT/WT mice. At later stages, L1 transcripts returned to basal levels in 
both WT/WT and WT/KI mice.  
Interestingly, for all the three L1 subfamilies we described almost overlapping L1 
expression profiles (figure 22 a,b,c).  
In conclusion, these findings show that in the striatum, excluding the stage of 
12mo, L1 expression levels and profiles are similar between WT/WT and WT/KI mice 
and L1s undergo a wave of transcription during late embryonal development. 
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Figure 22. Endogenous L1 expression profiles during development of striatum. a) Expression 
analysis of full length L1 Gf elements in WT/WT (left, light blue) and WT/KI (right, dark red) mice. b) 
Expression analysis of full length L1 A elements c) Expression analysis of full length L1 Tf elements. 
E10, embryonal day 10; E12, embryonal day 12; E14, embryonal day 14; E17, embryonal day 17; P0, 
date of birth; 3M, 3 months, 12M, 12months; 24M, 24months. Relative quantification of L1 5’UTR 
mRNA were normalized with the housekeeping gene UbC. Each dot represents average value of 6 
independent biological replicas. Error bars represent standard error. *P<0.05, **P<0.01 resulting from 
Mann Whitney unpaired test. Statistical significance is relative to the previous developmental stage. 
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L1 expression profiles in cerebral cortex 
In cerebral cortex, similarly to the striatum, L1 elements appeared to be actively 
transcribed and underwent a wave of transcription during embryonal development.  
In embryonal stages, as shown in figure 23, we could evidence marked similarities 
in L1 expression profiles of WT/WT and WT/KI mice. In detail, L1 expression 
increased from E10 to E14, especially between E10 and E12. Then, at E14, the peak of 
L1 expression during neuronal embryogenesis was reached in both WT/WT and WT/KI 
mice. Until P0, L1 mRNA levels progressively decreased. 
Later on, at post-natal stages, in WT/WT mice (figure 23, left panels), L1 
transcription increased from P0 to 3mo at statistically significant levels for 5’A and 5’Tf 
elements. Between 3mo and 12mo, mRNA levels remained stable for 5’Gf, but 
decreased for 5’A and increased for 5’Tf subtype. Then, along with senescence (from 
12 mo to 24 mo) L1 mRNA expression of all three subfamilies substantially decreased. 
On the other hand, in adult WT/KI mouse brains (figure 23, right panels), L1 
expression profiles showed a marked, statistically significant, increase of L1 elements 
between P0 and 3mo and this was consistent in all three L1 5’UTR subfamilies. 
However, with time (from 3 mo to 24 mo) L1 activation tended to decrease.  
As previously described, in post-natal stages of WT/KI cortices, apart from 12mo, 
L1 mRNA levels remained higher when compared to WT/WT mice (see also figure 21). 
Noteworthy, also in the case of cerebral cortex, we observed similar expression 
profiles for Gf, A and Tf L1 elements. This was true particularly during embryonal 
development (figure 21 a,b,c). 
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Figure 23. Endogenous L1 expression profiles during development of cerebral cortex. a) 
Expression analysis of full length L1 Gf elements in WT/WT (left, light blue) and WT/KI (right, dark red) 
mice. b) Expression analysis of full length L1 A elements. c) Expression analysis of full length L1 Tf 
elements. E10, embryonal day 10; E12, embryonal day 12; E14, embryonal day 14; E17, embryonal day 
17; P0, date of birth; 3M, 3 months, 12M, 12months; 24M, 24months. Relative quantification of L1 
5’UTR mRNA were normalized the housekeeping gene UbC. Each dot represents average value of 6 
independent biological replica. Error bars represent standard error. *P<0.05, **P<0.01, ***P<0.001 
resulting from Mann Whitney unpaired test. Statistical significance is relative to the previous 
developmental stage. 
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1.4. ORF2 protein expression in adult mouse brain 
Full length L1 mRNA is a bicistronic transcript that encodes for ORF1 and ORF2 
proteins (ORF1p and ORF2p). ORF1p is an RNA binding protein with chaperone 
activity (Martin, 2006), whereas ORF2p has both endonuclease and reverse 
transcriptase activities (Ostertag and Kazazian, 2001). Together these two proteins bind 
to L1 mRNAs or to non-autonomous retrotransposons mRNAs to form a 
ribonucleoprotein complex that mediates reverse transcription (TPRT) and genomic re-
integration of the retrotransposon.  
We next decided to investigate whether the L1 mRNAs endogenously transcribed 
in the adult brain can lead to detectable levels of ORF2p and, if so, whether this is a 
common feature among striatal and cortical neurons or if it is restricted to a subset of 
cells. To this purpose, using immunofluorescence analysis, we interrogated the 
expression and localization of ORF2 protein in striatum and cortex of WT/WT
 
and 
WT/KI adult mice (3mo, 12mo and 24mo). 
As shown in figure 24, we couldn’t detect any ORF2p staining in the striatum of 
WT/WT or WT/KI mice at 3mo, 12mo and 24mo of age. This might suggest that the 
protein is not expressed in this tissue or that levels of expression are under the detection 
threshold. 
However, we could evidence the presence of ORF2p-positive cells in some 
regions of the cerebral cortex. Expression levels were overall low. ORF2p-expressing 
neurons localized particularly in outer cortical layers of the pre-frontal cortex, in those 
areas corresponding to primary motor cortex (highlighted with a red square in the 
representative bright-field image of mouse brain coronal section on the top of figure 
24). 
The staining for ORF2p in prefrontal cortex cells display prevalently a 
cytoplasmic signal even though some ORF2 positivity was detected in few nuclei 
(figure 24). ORF2p appears to be expressed in a subset of cells of the region analyzed. 
Similar patterns of ORF2p expression were observed in 3mo, 12 mo and 24mo 
cortices, in both WT/WT
 
and WT/KI
 
mice. 
In summary, this analysis revealed that the endogenous ORF2p protein can be 
detected in the pre-frontal cortex of adult mice. Noteworthy, ORF2p expression is not a 
common feature of pre-frontal cortical neurons but is limited to a small subset of them. 
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Figure 24. ORF2 protein expression in adult mouse brains Representative figure of L1 ORF2p 
immunostaining in coronal brain sections (0.3 mm from Bregma) of 3months, 12 months, 24 months old 
WT/WT and WT/KI mice (n=4). Nuclear staining with DAPI is shown in blue. L1ORF2p signal is shown 
in green. Immunostaining using only secondary antibody is used as negative control. 
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2. Study of regulatory pathways of L1 retrotransposition in HD 
mouse brains 
2.1. Analysis of L1 transcriptional mechanisms 
During evolution, cells developed surveillance mechanisms to prevent L1 
transposition, acting both at transcriptional and post-transcriptional levels. The control 
of L1 mRNA at a transcription level can occur mainly through 1) binding of 
transcription factors; 2) DNA methylation at the CpG rich region on L1 5’UTR, 
mediated mainly by de novo methyltransferases in germline (Bourch’his et al.,2004), 
and by methyl-CpG-binding protein 2 (MeCP2) in somatic tissues (Muotri et al. 2010); 
3) epigenetic modifications on histone tails able to remodel chromatin status on L1 
promoter. In particular, L1s are constitutively repressed by H3K9me3 in somatic cells, 
but their expression can be modulated by loss or acquisition of diverse repressive or 
active histone marks (i.e. H3K4me3), that finally lead to enhanced L1 activation or 
repression, as observed especially during spermatogenesis (Fadloun et al.2013, (Pezic et 
al., 2014) Rangasamy et al.,2013). 
In HD, several epigenetic alterations have been reported, including alterations of 
methylation on histone tails and aberrant interaction between mutant huntingtin and 
MeCP2, leading to transcriptional dysregulation of target genes (McFarland et al.,2014, 
Ryu et al.,2006, Vashishtha et al 2013, Biagioli et al.,2015).  
Therefore, we asked whether the reduced L1 expression detected in the striatum of 
12mo WT/KI mice could be associated to some of the epigenetic alterations described 
in HD brains. To this purpose, we interrogated the methylation status of histone tails on 
L1 promoter together with the level of MeCP2 association to L1 5’UTR. 
H3K4me3, H3K9me3, H3K27me3 association to L1-5’UTR 
Elevated levels of trimethylation at H3K9 (H3K9me3) are detected in HD 
striatum (Ryu et al., 2006). Moreover, mutant huntingtin enhances polycomb repressive 
complex 2 (PRC2) activity by direct interaction, which, in turn, affects the deposition of 
H3K27me3 and H3K4me3 on bivalent loci of genes crucial for neuronal identity and 
survival (Biagioli et al., 2015; Seong et al., 2010; von Schimmelmann et al., 2016). 
Therefore, as a first step, we checked whether these three histone modifications 
(H3K9me3, H3K4me3 and H3K27me3), known to be altered in HD, might account for 
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the reduced L1 expression in 12mo HD striatum. To this purpose, using qPCR, we 
compared the levels of L1 5’UTR enrichment in WT/WT and WT/KI mice after 
chromatin immunoprecipitation with specific antibodies for each histone mark.  
For each chromatin immunoprecipitation experiment, we first assessed the level 
of enrichment obtained for the immunoprecipitated (IP) sample compared to the relative 
IgG. According to the literature (Chen-Plotkin et al., 2006), if the enrichment for IP 
versus IgG was lower than 1.5, samples were discarded. After that, to overcome the 
huge variability detected between replicas, and to compare the levels of L1 5’UTR 
enrichment in WT/WT and WT/KI mice, we normalized the IP/input fraction obtained 
for L1 5’UTR on that obtained for a gene desert region not associated to H3K9me3, 
H3K27me3 and H3K4me3. With this approach, we can adjust the background level 
derived from aspecific immunoprecipitated DNA.  
As shown in figure 25, from ChIP analysis on H3K4me3 histone mark, typically 
associated with active chromatin, we obtained acceptable levels of IP enrichment as 
compared to relative IgG for all the striatal samples (4 WT/WT and 4 WT/KI ) (figure 
25a). However, when we compared the L1 5’UTR enrichment between striatum of 12 
mo WT/WT and WT/KI mice, we could not appreciate any significant quantitative 
difference (figure 25b). Scatter plots show the result of four independent biological 
replicas and suggest the presence of a high level of variability between replicas in both 
WT/WT and WT/KI mice, even after the normalization to the gene desert region. 
Similar results were obtained from the analysis of H3K9me3 and H3K27me3 
repressive histone marks. In particular, for H3K9me3 we discarded samples nr. 2 and 
nr. 3 (corresponding to 1 WT/WT and 1 WT/KI mice) because of unsuccessful 
immunoprecipitation compared to the relative IgG (figure 26a). The L1 5’UTR relative 
enrichment analysis revealed a high interindividual variability, particularly in WT/KI 
samples. Overall, after immunoprecipitation, we detected comparable levels of L1 
5’UTR enrichment in WT/WT and WT/KI mice (figure 26b).  
Chromatin immunoprecipitations using H3K27me3, indicator of silenced 
chromatin, showed high levels of IP versus IgG enrichment in all the 8 samples 
analyzed, suggesting high efficiencies of chromatin immunoprecipitation (figure 27a). 
However, as well as for H3K4me3 and H3K9me3 ChIPs, we could not detect 
quantitative differences of L1 5’UTR association levels to H3K27me3 in the striatum of 
WT/WT compared to WT/KI mice (figure 27b).  
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Overall, from our chIP analyses on histone marks, we were not able to show 
altered methylation status of histone tails on L1 5’UTR that could explain the reduced 
L1 expression in the striatum of 12mo HD mice.  
 
 
Figure 25. H3K4me3 association to L1-5’UTR. a) ChIP raw data for L1-5’UTR Gf in IP 
samples (light grey) compared to respective IgG (dark grey). The data are calculated as % of IP/input and 
numeric values of each replica are indicated in the bottom table. X-axis values label the number of 
biological replica. b) Enrichment of L1-5’UTR Gf after immunoprecipitation with H3K4me3 antibody in 
the striatum of 12 months old WT/WT compared to WT/KI mice. Values for each IP sample were first 
adjusted to respective INPUT sample. Then adjusted 5’UTR values were normalized on those of a gene 
desert sequence used as negative internal normalizer. Main horizontal black line indicates the average 
value of 4 biological replicas. Error bars indicate standard deviation. 
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Figure 26. H3K9me3 association to L1-5’UTR. a) ChIP raw data for L1-5’UTR Gf in IP 
samples (light grey) compared to respective IgG (dark grey). The data are calculated as % of IP/input and 
numeric values of each replica are indicated in the bottom table. X-axis values label the number of 
biological replica. b) Enrichment of L1-5’UTR Gf after immunoprecipitation with H3K9me3 antibody in 
the striatum of 12 months old WT/WT as compared to WT/KI mice. Values for each IP sample were first 
adjusted on respective INPUT sample. Then adjusted 5’UTR values were normalized on those of a gene 
desert sequence used as negative internal normalizer. Main horizontal black line indicates the average 
value of 3 biological replicas. Error bars indicate standard deviation. 
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Figure 27. H3K27me3 association to L1-5’UTR. a) ChIP raw data for L1-5’UTR Gf in IP 
samples (light grey) compared to respective IgG (dark grey). The data are calculated as % of IP/input and 
numeric values of each replica are indicated in the bottom table. X-axis values label the number of 
biological replica. b) Enrichment of L1-5’UTR Gf after immunoprecipitation with H3K27me3 antibody 
in the striatum of 12 months old WT/WT as compared to WT/KI mice. Values for each IP sample were 
first adjusted on respective INPUT sample. Then adjusted 5’UTR values were normalized on those of a 
gene desert sequence used as negative internal normalizer. Main horizontal black line indicates the 
average value of 4 biological replicas. Error bars indicate standard deviation. 
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MeCP2 association to L1-5’UTR 
In addition to the study of histone modifications on L1 promoter, using a similar 
approach, we interrogated MeCP2 binding to L1 5’UTR in the striatum of 12mo mice. 
MeCP2 promotes L1 silencing by binding to L1 5’UTR (Muotri et al., 2010) and it is 
able to interact with huntingtin in a polyQ-dependent fashion with a consequent 
increase in MeCP2 silencing on target genes (McFarland et al., 2014).  
Therefore, we performed ChIP-qPCR analysis in order to assess the association 
levels of MeCP2 to 5’UTR L1 sequences in the striatum of 12 mo HD mice compared 
to controls.  
As shown in figure 28, similarly to what observed with the histone marks, a high 
degree of variability between replicas was detected with MeCP2 ChIP experiments. We 
obtained reliable enrichments for L1 5’UTR sequences in 6 out of 8 IP samples, so that 
we discarded samples nr. 1 and nr. 5 in the final analysis (figure 28a). 
When we compared the 5’UTR enrichment levels of MeCP2-precipitated 
chromatin fractions between WT/WT and WT/KI mice, we observed a slight increase in 
the striatum of WT/KI mice, but this difference was not statistically significant (figure 
28b), suggesting that additional replicas are needed to overcome the interindividual 
variability. 
 
Taken together these data suggest that HD-specific epigenetic alterations exerted 
by H3K4me3, H3K9me3, H3K27me3 and MeCP2 do not directly affect L1 5’UTR 
transcription in the striatum of 12 mo Hdh 
Q7/Q111
 mice.  
However, in all these ChIP experiments we highlighted huge degrees of inter-
replica variability, suggesting that ChIP followed by L1 5’UTR qPCR probably cannot 
represent an enough sensitive technique for the detection of small differences of highly 
abundant genomic repeats with such ubiquitous chromatin binding proteins. 
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Figure 28. MeCP2 binding to L1-5’UTR. a) ChIP raw data for L1-5’UTR Gf in IP samples 
(light grey) compared to respective IgG (dark grey). The data are calculated as % of IP/input and numeric 
values of each replica are indicated in the bottom table. X-axis values label the number of the biological 
replica. b) Enrichment of L1-5’UTR Gf after immunoprecipitation with MeCP2 antibody in the striatum 
of 12 months old WT/WT compared to WT/KI mice. Results are calculated as % of IP/input. Main 
horizontal black line indicates the average value of 3 biological replicas. Error bars indicate standard 
deviation. 
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2.2. Analysis of L1 post-transcriptional mechanisms 
The piRNA pathway is one of the main sources of post-transcriptional L1 
silencing. First discovered in Drosophila melanogaster, this pathway is active primarily 
in the germline. MILI and MIWI2 are the murine homologs of Drosophila PIWI 
proteins and represent the two main factors of piRNA biogenesis, playing crucial roles 
in promoting de novo DNA methylation on L1 promoters (Kuramochi-Miyagawa et al. 
2008, Aravin et al. 2008). Very recent reports identified and proposed potential activity 
of piRNA pathway also in the mouse brain (Ghosheh et al., 2016, Nandi et al. 2016), 
suggesting the existence of a conserved mechanism that regulates retrotransposon 
silencing among eukaryotes. In line and simultaneously to these two works, we 
interrogated the potential involvement of the piRNA pathway in the regulation of L1 
expression in the adult brain of our mouse model. To this purpose, we analyzed the 
endogenous expression of MIWI2 and MILI in the striatum and the cortex of adult 
WT/WT and WT/KI mice. 
MILI expression in adult mouse brain 
First, using RT-PCR, we assessed the presence of MILI transcript in the cortex 
and striatum of adult WT/WT and WT/KI mice, using testis sample as a positive 
control. As shown in figure 29a, appreciable levels of endogenous MILI mRNA were 
detected in both nervous tissues analyzed, in WT/WT as well as in WT/KI mice and in 
all the three adult ages that we considered. 
Accordingly, MILI protein expression was confirmed by western blot analysis in 
both striatum and cortex of 3mo and 12 mo mice. As expected, MILI protein levels in 
brain tissues were much more reduced as compared to those expressed in testis (figure 
29b).  
Additionally, by immunohistochemistry on coronal brain sections of 12 mo mice, 
we detected MILI positive neurons in cerebral cortex and striatum with a prevalent 
cytoplasmic staining (figure 29c), consistent with what published by Nandi et al., 2016. 
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Figure 29. MILI expression in striatum and cortex of adult mouse brain. a) RT-PCR of MILI 
on cDNAs obtained from striatum, cortex and testis samples of adult WT/WT and WT/KI mice. Testis is 
used as positive control sample. b) Representative western blot showing MILI protein expression in 
striatum and cortex of 3 months and 12 months old mice (n=4). β-actin is used as loading control. c) 
Immunofluorescence staining of MILI protein in testis (positive control) and 16uM coronal brain sections 
of 12mo mice. Nuclear staining with DAPI is shown in blue. MILI staining is shown in green. 
Immunostaining using only secondary antibody is used as negative control. 
Results 
86 
 
Then, we asked if any correlation between MILI expression and L1 mRNA 
reduction could be evidenced in the striatum of HD mice at 12mo of age. To this aim, 
we performed qPCR experiments to assess MILI transcript levels in WT/KI relative to 
WT/WT mice.  
Unfortunately, as shown in figure 30, qPCR analysis did not reveal significant (p-
value=0.068) quantitative differences in MILI expression between WT/KI and WT/WT 
mice. 
Nonetheless we must consider that in this study we focused on MILI, thus giving 
no information about the types of piRNAs expressed in HD striatum, that represent the 
direct regulators of L1 expression. Therefore, it would be interesting to explore whether 
selected piRNA subsets are differentially expressed in WT/WT compared to WT/KI 
mice. 
 
 
Figure 30. MILI expression in striatum of 12mo WT/WT as compared to WT/KI mice. RT-
qPCR analysis revealed no significant differences in MILI transcript levels between WT/WT and WT/KI 
mice. MILI transcript levels are normalized with housekeeping gene UbC. Horizontal black lines indicate 
average value of 12 independent biological replica (n=12). Error bars display standard deviation.  
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MIWI2 expression in adult mouse brain 
At the same time, we also tested the expression of the second player of the piRNA 
pathway: MIWI2. To this purpose, we assessed MIWI2 expression by RT-PCR and WB 
analyses in adult brain tissues.  
As expected from the literature, we detected high levels of MIWI2 in testis but 
undetectable levels of MIWI2 expression in the two nervous tissues analyzed (cortex 
and striatum). This was confirmed by both RT-PCR and Western blot analyses (figure 
31). 
Therefore, taken together, these data provide an additional independent evidence 
of MILI expression and MIWI2 absence of expression in the adult mouse brain. This 
result supports the idea of a functional role of MILI not only in the germline but also in 
mammalian adult brain and consequently suggests a function of MILI associated 
piRNAs outside germ cells, as proposed by Nandi and colleagues. 
 
 
Figure 31. MIWI2 expression in striatum and cortex of adult mice. a) RT-PCR of MIWI2 on 
cDNAs obtained from striatum, cortex and testis samples of adult WT/WT mice. Testes are used as 
positive control samples b) Representative Western Blot showing MIWI2 protein expression in testis 
samples but not in striatum and cortex of 12 months old mice (n=3). β-actin is used as loading control.
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DISCUSSION 
“Insertional mutagens” and “regulatory elements”, with these words geneticist 
Barbara McClintock first described a class of “mutant loci” that she discovered be 
responsible for altered kernels’ pigmentation in maize. After her seminal work, these 
“mutant loci” were identified as transposable elements (TEs), a class of repetitive 
genomic sequences able to mobilize from one site to another within the genome. Owing 
to their mobilization capabilities, TEs accumulated over time in almost all eukaryotic 
genomes and equipped host genomes with useful tools of plasticity and evolutionary 
adaptation. Overall, TEs compose almost 40% of human and mouse genomes.  
L1s are far and away the most active TEs in mammalian genomes. They compose 
17% and 19% of human and mouse genomes, respectively, and mobilize via the L1 
retrotransposition process, a “copy and paste” mechanism where a L1-RNA 
intermediate is first “copied” and then reverse-transcribed and “pasted” in a new 
genomic location. L1 retrotransposons can mediate mobilization of their own transcripts 
and of other non-L1 retrotransposons mRNAs, thus significantly affecting genomes’ 
structure and function. By promoting new retrotransposons insertions, L1s can lead to 
genomic rearrangements and remodeling of transcriptional units. At the same time, L1 
mRNA and L1-encoded proteins, even without resulting in a new genomic transposon 
insertion, can perturb cellular functions by providing cells with additional sources of 
endonucleases, reverse transcriptases and potentially non-coding RNAs. Consequently, 
to prevent potential deleterious effects of L1 abnormal activity, cells have developed 
several mechanisms to safeguard and fine-tune L1 retrotransposition. At the end, the 
balance between evolutionary advantages of L1 mobilization and L1 regulation 
generates L1 permissive environments fundamental for organismal biology. In 
particular, germ cells experience the highest levels of L1 activity due to their flexible 
methylation signatures and therefore giving the opportunity to new favorable L1 
insertions to be passed on future generations. Similarly, the first phases of embryonal 
development seem to be particularly tolerant to L1 retrotransposition. Interestingly, in 
the last decade, an increasing number of evidence is showing that also somatic cells of 
the adult brain can support L1 mobilization. L1 retrotransposition events have been 
extensively described during neurogenesis and recently in terminally differentiated 
neurons. Single cell genomic studies estimated that at least 0.6 L1 retrotransposition 
events per neuron occur in adult human hippocampus and frontal cortex. This feature is 
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evolutionary conserved from Drosophila to mammals and represent a major source of 
somatic mosaicism in adult central nervous system, suggesting its crucial role for 
normal brain physiology.  
Conversely, unregulated activation of L1s associates with neuropathology, as 
observed in Rett syndrome, Ataxia telengectasia and schizophrenia.  
Considering these recent findings, we asked whether L1 retrotransposition could 
be altered in Huntington’s disease (HD) and, in turn, if L1 retrotransposition could 
affect HD pathogenesis.  
HD is a late-onset, autosomal dominant disorder caused by a CAG expansion in 
the IT15 gene that leads to the production of a mutated toxic form of huntingtin protein. 
Since the discovery of the gene responsible for the pathology, an impressive amount of 
data on the molecular basis of HD neurodegeneration accumulated, however relatively 
little is known about the genetic and epigenetic factors that could be crucial in 
modulating disease onset and pathology progression. For instance, the basis of somatic 
CAG expansion leading to a consequent anticipation of symptoms remains largely 
unclear. On the other hand, the presence in HD brains of extensive epigenetic 
alterations, transcriptional dysregulation, neuronal specification impairments and DNA 
damage could have important effects on several cellular processes, including L1 
retrotransposition.  
Here, using a novel qPCR Taqman assay we assessed the expression of full length 
active murine L1 elements during mouse brain development (from E10 to 24 mo) in a 
genetically precise mouse model of HD. With these analyses, we showed that HD mice 
display an altered expression of L1 mRNAs. Additionally, we observed that the 
endogenous transcription of L1 elements can lead to the expression of ORF2 protein in 
a particular subset of neurons of the adult frontal cortex, both in WT and HD conditions. 
Moreover, we highlighted that L1 elements undergo a wave of transcription during 
cortical and striatal embryonic development which is then maintained at basal levels 
after birth. Finally, we provide additional evidence of a functional piRNA pathway in 
the adult mammalian brain.  
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1. L1 expression dysregulations in HD mouse brain  
In this study, taking advantage of Hdh 
Q7/Q111
 knock-in (WT/KI) mice, for the first 
time we assessed L1 retrotransposition in the cerebral cortex and striatum of a precise 
genetic model of HD. In order to monitor the entire disease progression, we performed 
L1 retrotransposition characterization in the adult mouse as well as in embryonal stages, 
at both genomic and transcriptional levels. 
From a genomic point of view, by performing L1 copy number variation analysis 
using a qPCR-based approach targeting L1-ORF2 sequences, we were not able to 
evidence differences in genomic L1 content between HD and control mice. This was 
true both in striatum and cortex and in all the developmental stages analyzed. This result 
was very informative, but at the same time, as already proposed by others (Goodier 
2016), it might be biased by the fact that qPCR analyses on bulk tissues likely 
underestimate L1 insertion events that are private for a small subset of cells within a 
tissue. Therefore, to finely characterize the genomic content of L1 elements in a tissue 
and to accurately compare it between different samples, it would be useful to perform 
relative L1 copy number quantification after the sorting of a selected number of cells, a 
procedure that is becoming a gold standard in this field after its first application (Bundo 
et al.,2014). 
Nonetheless, even if the genomic L1 content seems to be equivalent in HD and 
WT mice, we decided to study endogenous L1 expression in HD adult mouse brains. To 
this purpose, we first performed a relative quantification analysis of full length L1 
transcripts, distinguishing between the three active murine L1 subfamilies, in striatum 
and cortex of HD mice as compared to controls. Then we assessed the endogenous 
expression of ORF2 protein that is autonomously encoded by full length L1 elements. 
These experiments highlighted L1 expression alterations in HD brains, affecting both 
cortex and striatum.  
In the cerebral cortex, we showed that L1 Gf elements are overexpressed in 3 mo 
old HD mice and that all three L1 subfamilies are consistently overexpressed at 24 mo 
of age, while no alterations are detected at 12mo of age, in late embryos and at P0. 
Moreover, in both HD and control adult mice, from the age of 3mo up to 24 mo, 
endogenous levels of ORF2p were detected by immunohistochemistry in a small subset 
of neurons of the pre-frontal cortex. ORF2p staining was mostly cytoplasmatic, as 
expected from the literature (Gualtieri et al., 2013). Although we did not reveal 
significant differences in ORF2p staining between WT and HD mice, the detection of 
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an endogenous signal for ORF2p in a non-pathological tissue represented an important 
finding, considering the great efforts generally required to detect this protein (Doucet et 
al., 2010). Therefore, we might conclude that in a subpopulation of neurons of the pre-
frontal cortex, endogenous L1 mRNAs are translated to produce appreciable levels of 
ORF2p. This would be in agreement with the neuronal L1 retrotransposition that has 
been reported in somatic cells of the adult frontal cortex in mammalian brains (Erwin et 
al., 2016). 
On the other hand, the overexpression of L1 elements detected at 3 mo and 24 mo 
in mutant huntingtin-expressing brains, might represent a novel pathological feature of 
HD, arising already at pre-symptomatic stages (3mo). The mechanisms underlying these 
alterations remain largely unclear and could be related to aberrant transcriptional or 
epigenetic programs, previously described in HD cortical neurons (McKinstry et al., 
2014, Gauthier et al., 2004).  
Concerning very old 24 mo mice, we speculate that HD conditions, in the cortex, 
might somehow exacerbate the process of L1 activation normally occurring in aging 
brains (Van Meter et al.,2014, Li et al.,2013), in turn rendering HD-affected cortical 
neurons more susceptible to neurodegeneration. 
From the same analysis performed in the striatum of HD mice, we could not 
detect appreciable levels of ORF2p expression. Additionally, no differences have been 
evidenced in L1 expression between WT and HD mice during embryonal development, 
at P0, at 3mo and at 24 mo. However, at 12mo, we interestingly observed a significant 
decrease in L1 transcript levels in the striatum of HD mice that was consistent in all the 
three murine L1 subfamilies. Notably, this finding represented a strong evidence of L1 
transcriptional dysregulation at the age and in the brain region where the major HD-
pathological phenotypes accumulate. Therefore, we then asked whether L1 repression in 
the striatum of 12mo HD mice could relate to altered L1 epigenetic regulation. 
Noteworthy, at 12mo of age, several molecular alterations triggered by mutant 
huntingtin have been described in the striatum of Hdh 
Q7/Q111
 mice (Wheeler et al., 
2002). These observations include altered methylation of DNA and of histone tails. 
Therefore, we assessed the levels of L1-5’UTR enrichment after chromatin 
immunoprecipitation with different chromatin remodelers known to be associated with 
L1 promoter and to be altered in HD pathology. We specifically chose H3K9me3, 
H3K27me3, H3K4me3 histone marks and MeCP2 for our analysis. Unfortunately, none 
of these regulators could be linked to altered L1 expression in HD striatum, suggesting 
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that other factors could underlie this phenomenon or that the technique that we 
employed was not sensitive enough in our experimental conditions.  
We then decided to investigate the potential involvement of the piRNA pathway 
in the regulation of L1 expression in HD striatum. Indeed, it has been recently 
demonstrated that piRNAs could be functional in adult mouse brains (Nandi et al., 
2016) and abnormal miRNA expression and miRNA biogenesis have been reported in 
HD brains (Johnson et al., 2008; Packer et al., 2008, Lee and Kim, 2011). To this aim, 
we interrogated in our samples the expression of MILI, the protein able to bind piRNAs 
and target them to transposons mRNAs for their silencing. Surprisingly, we detected 
appreciable levels of MILI expression in adult brains but it did not correlate with L1 
deregulation in the striatum of 12mo HD mice. We have to consider however that, by 
addressing MILI expression, we do not obtain any information about piRNAs 
expression. Therefore, it would be interesting to assess whether piRNAs are 
differentially expressed in HD mice as compared to WT. This in turn could explain 
altered regulation of L1 mRNAs in HD brains.  
An alternative mechanism of modulation of retrotransposons’ activity in a context 
of HD, particularly in the striatum, could be mediated by PRC2, whose activity is 
known to be influenced by huntingtin protein in a polyQ-dependent fashion (Seong et 
al.,2010). In fact, PRC2 plays a crucial role in suppressing transcriptional programs that 
otherwise would be detrimental for striatal neurons’ function and survival 
(VonSchimmelmann et al.,2016). Moreover, PRC2 can repress expansion of parasitic 
DNA, like endogenous retroviruses (Leeb et al., 2010). 
In alternative to the “aberrant regulatory” hypothesis, to explain L1 
downregulation in 12mo HD striatum, we can hypothesize a selective neuronal loss of 
striatal neurons expressing L1 transcripts. In this case, L1 expression could represent a 
susceptibility factor for enhanced neurodegeneration in HD striatum. Notably, at 12 
months of age, this phenomenon would be accompanied by extensive DNA damage 
(Wheeler et al., 2002). 
In summary, these findings provide the first description of L1 retrotransposition in 
a defined genetic mouse model of HD. Interestingly, our analysis shows that altered 
expression of L1 elements occurs in both striatum and cerebral cortex of HD mice. In 
cortex, L1 overexpression appears both at early and late stages, whereas in the striatum, 
L1 downregulation occurs later, when many pathological HD phenotypes are manifest. 
In both cases, L1 retrotransposition might represent a previously unrecognized 
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modulator of HD age at onset and progression. However further studies are needed to 
better understand if L1 activity is driver or bystander of HD neuropathogenesis.  
2. Endogenous L1 expression dynamics during striatal and cortical 
development 
The study of L1 expression in striatum and cortex of E10, E12, E14, E17, P0, 
3mo, 12mo and 24 mo old mice, allowed us to describe the expression profiles of full 
length L1 elements in WT as well as HD mice. With these experiments, we provided the 
first complete characterization of endogenous L1 expression in striatum and cortex 
during late embryonal development (between E10 and P0) and the entire adulthood of 
murine life. Expression dynamics were outlined for all the active L1 subfamilies present 
in the mouse genome: Gf, A and Tf L1s. 
We interestingly observed that, during late embryonal development, L1 mRNA of 
all the three L1 subtypes are actively transcribed in both cortex and striatum. L1 
elements undergo a wave of transcription between E10 and P0, reaching their highest 
levels between E14 and E17 in both tissues. Notably, L1 transcription dynamics are 
almost overlapping in WT and HD mice, thus highlighting a common feature of mouse 
cortical and striatal embryogenesis.  
Interestingly, we noticed an extraordinary parallelism between L1 expression 
profiles and the wave of neurogenesis that takes place during differentiation of 
embryonal telencephalon, the brain structure comprising cerebral cortex and striatum 
(Götz and Huttner, 2005). When the highest number of newly born neurons is reached, 
the bulk of L1 transcription is registered. On the other hand, as neurons in excess start 
to physiologically die, a reduction of L1 expression follows. These findings seem to be 
in agreement with the idea that L1 overexpression associates with neuronal death. 
Therefore, L1 activation seems to be a mechanism with a dual role, strictly related to the 
context in which it takes place: in some cases it can take part to developmentally crucial 
functions, as described in embryonal neurogenesis and fetal oocyte attrition (Malki et 
al., 2014); in other cases, it can be toxic for the cell, potentially leading to an increased 
susceptibility to neurodegeneration, as hypothesized for the striatum of 12mo HD mice. 
After birth, L1 expression profiles show that L1 mRNAs are generally maintained 
at basal levels, although, from 3mo to 12 mo, we unexpectedly observed an increase in 
L1 transcription in physiological conditions in the striatum. This event is consistent for 
the three L1 subfamilies. At present, its biological significance remains unclear.  
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By contrast, the analysis of adult cerebral cortex revealed less conserved 
expression profiles between L1 Gf, A and Tf subfamilies. We think that this could 
reflect the neuronal heterogeneity typical of the cerebral cortex that is not present in 
other brain regions, like striatum or cerebellum. 
In summary, this study allowed us to provide a complete depiction of endogenous 
L1 expression dynamics during the development of central nervous system, with 
particular attention to striatal and cortical brain regions. With this approach, we 
interestingly unveiled a wave of L1 transcription mirroring embryonal telencephalic 
neurogenesis. 
3. MILI expression in adult mouse brain 
In view of recent findings showing piRNAs expression in adult mammalian brain 
(Nandi et al.,2016; (Ghosheh et al., 2016)) and considering previous RNA-seq data 
obtained in our group showing expression of MILI in the striatum of 12mo mice, we 
begun to explore the expression of piRNA biogenesis factors in our brain samples. 
From this analysis, consistent with the literature, we did not find evidence of MIWI2 
expression in the brain of adult mice. However, as expected, the presence of MILI in 
adult striatum and cerebral cortex was confirmed by RT-PCR, Western Blot and 
immunohistochemistry. In the mouse brain, MILI seems to be expressed throughout the 
entire adulthood, thus indicating a common feature of adult mouse brain, not restricted 
to particular developmental stages. Furthermore, by histological studies, we showed that 
MILI is expressed mainly outside the nucleus, therefore suggesting that in the brain 
MILI probably participate in the load of cellular piRNAs or other endogenous siRNAs 
to promote post-transcriptional silencing of target mRNAs. Alternatively, we can expect 
that in the brain, similarly to the germline, MILI might give rise to the “ping-pong” 
amplification cycle. Since the initiation of this cycle relies on the presence of 
retrotransposon mRNAs, we suppose that neuronal retrotransposons transcripts could be 
the source of piRNAs that are then loaded and processed by MILI to exploit their 
silencing function. However, due to the lack of MIWI2 expression, MILI could have 
taken over the role of MIWI2 in its capacity to silence retrotransposons in mouse adult 
brains.  
Our results, together with data published this year by Ghosheh et al., 2016 and 
Nandi et al., represent three independent evidence of expression of piRNAs and piRNA 
biogenesis factors in adult mouse brains, therefore robustly supporting the idea of a 
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functional role of piRNAs not confined to the germline. It will be interesting to 
investigate the expression of retrotransposons in adult brains of MILI null mice. With 
this experiment, we might understand whether the function of piRNA pathway in the 
adult brain is mainly a defense against retrotransposon propagation, as in the germline, 
or if new roles developed during evolution. We can for instance suppose that piRNAs in 
the brain could contribute to neuronal plasticity by acting on the cellular epigenome. 
Overall, if we think to the waves of retrotransposition that occurred during 
evolution, it is not surprisingly that factors involved in L1 mobilization in germ cells are 
related to factors acting in the brain. Indeed, it is thanks to the inter-generational 
transmission of advantageous insertional events, that L1 retrotransposition was passed 
to future generations, even promoting in some cases sexual reproduction success 
(Barsoum et al., 2010). Therefore, mechanisms that originally allowed 
retrotransposition in the germline should be similar to those existing in somatic cells. In 
line with this model, in silico data reported parallelisms between human brain and testes 
gene expression patterns (Guo et al., 2003, 2005) and it has been proposed that 
similarities in expression in brain and testes might play important roles for human 
speciation (Wilda et al., 2000). 
Altogether, our findings give additional evidence of active retrotransposition in 
adult mammalian brains, therefore strongly supporting the idea of L1 retrotransposons 
as sources of somatic mosaicism in this tissue. However, in this context many open 
questions need to be addressed. We know that eukaryotic genomes underwent important 
waves of retrotransposition during evolution and they have never lost their intrinsic 
patrimony of transposable elements, therefore displaying an inextricable link between 
L1s and host genomes. Accordingly, germline retrotransposition crucially contributed to 
the transmission of advantageous insertional events. But what is the meaning of L1 
retrotransposition in somatic cells? Which are the functions and mechanisms of somatic 
L1 insertions? Do genomes strictly need so many copies of the same element and why? 
Does L1 retrotransposition interest other somatic tissues, apart from brain and cancer? 
These are just some of the many questions that need to be addressed in the next future to 
have a complete overview of such an outstanding phenomenon, so powerful in creating 
somatic genomic variability within cells of the some tissue but at the same time having 
important implications in pathological processes. 
 .
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Figure 32. Expression analysis of L1 5’UTR Gf elements in striatum and cortex of WT/WT 
and WT/KI mice. Scatter plots display interindividual variability between biological replica at each 
developmental stage. E10, E12, E14, E17 means embryonal day 10, 12, 14, 17, respectively; P0, date of 
birth; 3mo, 3 months of age; 12mo,12months of age; 24mo, 24 months of age. Relative 5’UTR L1 mRNA 
levels are normalized with the housekeeping gene UbC gene. Each dot of the scatter plot represent the 
average of at least 3 independent qPCR replica. The average value between biological replica is shown 
with black horizontal line. Error bars indicate standard deviation. *P<0.05, **P<0.01 resulting from 
Mann Whitney unpaired test. 
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Figure 33. Expression analysis of L1 5’UTR A elements in striatum and cortex of WT/WT 
and WT/KI mice. Scatter plots display interindividual variability between biological replica at each 
developmental stage. E10, E12, E14, E17 means embryonal day 10, 12, 14, 17, respectively; P0, date of 
birth; 3mo, 3 months of age; 12mo,12months of age; 24mo, 24 months of age. Relative 5’UTR L1 mRNA 
levels are normalized with the housekeeping gene UbC. Each dot of the scatter plot represent the average 
of at least 3 independent qPCR replica. The average value between biological replica is shown with black 
horizontal line. Error bars indicate standard deviation. *P<0.05, **P<0.01 resulting from Mann Whitney 
unpaired test.  
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Figure 34. Expression analysis of L1 5’UTR Tf elements in striatum and cortex of WT/WT 
and WT/KI mice. Scatter plots display interindividual variability between biological replica at each 
developmental stage. E10, E12, E14, E17 means embryonal day 10, 12, 14, 17, respectively; P0, date of 
birth; 3mo, 3 months of age; 12mo,12months of age; 24mo, 24 months of age. Relative 5’UTR L1 mRNA 
levels are normalized with the housekeeping gene UbC. Each dot of the scatter plot represent the average 
of at least 3 independent qPCR replica. The average value between biological replica is shown with black 
horizontal line. Error bars indicate standard deviation. *P<0.05, **P<0.01 resulting from Mann Whitney 
unpaired test.  
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Figure 35. Comparison of full length L1 expression between striatum and cortex in adult 
mice. Relative quantification of 5’UTR Gf L1 mRNA transcript levels in striatum (black) and cortex 
(grey) of adult WT/WT and WT/KI mice. 3mo, 3 months of age; 12mo, 12 months of age; 24mo, 24 
months of age. Relative 5’UTR L1 mRNA levels are normalized with the housekeeping gene UbC. At 
3mo of age, L1 expression is significanty increased in the cortex as compared to the striatum. 3 
independent qPCR replica were performed on each biological sample. Each bar represent average value 
of twelve independent biological replica (n=12). Error bars indicate standard error. *P<0.05 resulting 
from Mann Whitney unpaired test. 
